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Despite the availability of several treatment regimens, obesity continues to be one of the greatest 
health challenges of the 21st century. In recent years, plant polyphenols have attracted increasing 
attention as nutraceuticals that are able to prevent or treat obesity and its co-morbidities. However, 
the first-line screening of these compounds is hampered by the shortage of in vitro experimental 
models that mimic the complex pathophysiology of obesity (excess lipid accumulation, basal 
lipolysis, inflammation and oxidative stress) in vivo. The aim of this study was two-fold. Firstly, 
establish a 3T3-L1 adipocyte in vitro model that more closely mimics obesity in vivo, and secondly 
to investigate the ameliorative properties of Aspalathus linearis, Cyclopia intermedia and their 
major polyphenols against these conditions.  
Methods 
For the experimental model, 3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 
mM glucose concentrations for 7 or 14 days. Lipid accumulation, basal lipolysis, oxidative stress, 
inflammation, mitochondrial activity and gene expression were assessed using Oil Red O staining, 
glycerol release, 2',7'-dichlorfluorescein-diacetate fluorescence to quantify reactive oxygen 
species, monocyte chemoattractant protein-1 secretion, the 3- [4, 5-Dimethylthiazol-2-yl]-2, 5 
diphenyltetrazolium bromide assay and quantitative real time polymerase chain reaction, 
respectively. The ameliorative effects of Aspalathus linearis (Afriplex GRTTM) and Cyclopia 
intermedia (CPEF) against these conditions were investigated by acute and chronic treatment of 
the optimised experimental model with various concentrations of these plant extracts and their 
major polyphenol Aspalathin and Mangiferin respectively. 
Results 
Collectively lipid accumulation, basal lipolysis, oxidative stress, inflammation and expression of 
associated genes were higher after differentiation in 33 mM for 14 days compared to lower glucose 
concentrations and 7 days, thus these conditions were selected as the experimental model. Neither 
acute nor chronic treatment with 0.1 to 100 µg/ml of Aspalathus linearis and Cyclopia intermedia, 
and 0.1 to 100 µM of Aspalathin and Mangiferin significantly decreased lipid content. However, 






Differentiation of 3T3-L1 pre-adipocytes in 33 mM glucose for 14 days increased basal lipolysis, 
oxidative stress and inflammation compared to lower glucose concentrations and differentiation 
for 7 days. Aspalathus linearis, Cyclopia intermedia, Aspalathin and Mangiferin ameliorated the 
increased basal lipolysis under these conditions. This study showed that differentiation in 33 mM 
glucose for 14 days may offer potential as an experimental model that more closely mimics obesity 
in vivo and may thus improve first-line screening for anti-obesity therapeutics. Aspalathus linearis, 
Cyclopia intermedia and their major polyphenol Aspalathin and Mangiferin, respectively may 





Ten spyte van die beskikbaarheid van verskeie behandelingsregimes, bly vetsug steeds een van die 
grootste gesondheidsuitdagings van die 21ste eeu. In die onlangse verlede het polifenole, 
afkomstig vanaf plante, toenemende aandag getrek as funksionele voedingsmiddels wat vetsug en 
die ko-morbiditeit daarvan kan voorkom of behandel. Die eerste-lyn-sifting van hierdie 
verbindings word egter belemmer deur die tekort aan in vitro eksperimentele modelle wat die 
komplekse patofisiologie van vetsug (oortollige lipiedakkumulasie, lipolise, inflammasie en 
oksidatiewe stres) in vivo kan naboots. Die doel van hierdie studie was tweeledig. Die eerste 
doelwit was om 'n 3T3-L1-adiposiet in vitro-model op te stel wat vetsug in vivo naboots, en 
tweedens om die verligtingseienskappe van Aspalathus linearis, Cyclopia intermedia en hul 
belangrikste polifenole teen hierdie toestande te ondersoek. 
Metodes 
Vir die eksperimentele model is 3T3-L1 pre-adiposiete vir 7 of 14 dae in 5.5 mM, 25 mM of 33 
mM glukosekonsentrasies gedifferensieer. Lipiedakkumulasie, lipolise, oksidatiewe stres, 
inflammasie, mitochondriale aktiwiteit en geenuitdrukking is onderskeidelik bepaal met behulp 
van “Oil Red O”-kleuring, gliserolvrystelling, 2', 7'-dichlorfluoresceïne-diasetaat fluoressensie om 
reaktiewe suurstofspesies te bepaal, monosiet chemo-aantrekkingskrag proteïen-1 sekresie, die 3- 
[4, 5-dimetieltiazol-2-yl]-2, 5 difenieltetrazoliumbromied-toets en kwantitatiewe reële tyd 
polimerase kettingreaksie. Die verbeteringseffekte van Aspalathus linearis (Afriplex GRTTM) en 
Cyclopia intermedia (CPEF) op hierdie toestande is ondersoek deur die akute en chroniese 
behandeling van die geoptimaliseerde eksperimentele model met verskillende konsentrasies van 
hierdie plantekstrakte en hul belangrikste polifenole, Aspalathin en Mangiferin, onderskeidlik. 
Resultate 
Lipiedakkumulasie, lipolise, oksidatiewe stres, inflammasie en uitdrukking van gepaardgaande 
gene was gesamentlik hoër na differensiasie in 33 mM glukose vir 14 dae in vergelyking met laer 
glukosekonsentrasies en 7 dae; dus is hierdie toestande as die eksperimentele model gekies. Nie 
akute of chroniese behandeling met 0,1 tot 100 µg/ml Aspalathus linearis en Cyclopia intermedia, 
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en 0,1 tot 100 µM Aspalathin en Mangiferin het die lipiedinhoud beduidend verlaag nie. Al die 
behandelings het egter lipolise verminder en mitochondriale aktiwiteit verhoog. 
Gevolgtrekking 
Differensiasie van 3T3-L1 pre-adiposiete in 33 mM glukose vir 14 dae het lipolise, oksidatiewe 
stres en inflammasie verhoog, vergeleke met laer glukosekonsentrasies en differensiasie vir 7 dae. 
Aspalathus linearis, Cyclopia intermedia, Aspalathin en Mangiferin het die verhoogde lipolise 
onder hierdie toestande verlig. Hierdie studie bewys dat die differensiasie in 33 mM glukose vir 
14 dae potensiaal bied as 'n eksperimentele model wat vetsug in vivo naboots en sodoende eerste-
lyn-sifting vir terapie teen vetsug kan verbeter. Aspalathus linearis en Cyclopia intermedia en hul 
belangrikste polifenole, Aspalathin en Mangiferin, toon dus potensiaal as antilipolitiese middels 
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Obesity is a multifactorial disorder characterised by the excessive accumulation of fat to the extent 
that it negatively affects health (Hruby & Hu, 2015). Recent estimates show that approximately 
641 million individuals worldwide (8.9%) are obese, with obesity rates projected to reach 20% by 
2025 (NCD-RisC, 2016). Obesity increases the risk of developing chronic disorders such as insulin 
resistance, type 2 diabetes (T2D), cardiovascular disease (CVD) and cancer (Haslam & James, 
2005). Although obesity was historically associated with developed countries, high rates are now 
reported in low- and middle-income countries (LMIC), driven by factors such as urbanisation, 
sedentary lifestyles and unhealthy diets (Ford, Patel & Narayan, 2017; Fox, Feng & Asal, 2019). 
Effective interventions are required to reduce the burden of obesity on health systems, particularly 
those in LMIC that are already over-burdened and under-resourced and least able to respond to the 
escalating obesity crisis. 
  
The mechanisms that underly the development of obesity and its complications are not yet fully 
elucidated, although several studies show that excessive energy intake leads to adipose tissue 
enlargement by hypertrophy (Jo et al., 2009; Sun, Kusminski & Scherer, 2011; Jung & Choi, 
2014). Adipocyte hypertrophy is associated with increased lipid accumulation, basal lipolysis, 
oxidative stress and inflammation. Excessive lipid accumulation and basal lipolysis leads to fatty 
acid (FA) secretion, with harmful effects on peripheral tissues such as the liver and muscle where 
it induces insulin resistance (Boden, 2011; Wang, Scherer & Gupta, 2014). Furthermore, adipocyte 
hypertrophy induces reactive oxygen species (ROS) and oxidative stress (Boden, 2011; Wang, 
Scherer & Gupta, 2014). In addition, adipocyte hypertrophy is associated with chronic low-grade 
inflammation (Shoelson, Herrero & Naaz, 2007; Boutens & Stienstra, 2016), which is mediated 
by the increased secretion of monocyte chemotactic protein (MCP1). This cytokine attracts pro-
inflammatory M1 macrophages to adipose tissue and decreases secretion of anti-inflammatory 
adipokines such as adiponectin (Jung & Choi, 2014). Together, all these co-morbidities of obesity 





Despite the availability of several anti-obesity strategies such as lifestyle modifications (mainly 
diet and exercise), pharmaceutical compounds and surgery for the morbidly obese, there is still a 
lack of safe, effective and long-term therapies. In recent years, plant polyphenols have attracted 
increasing attention as nutraceuticals that are able to prevent or treat obesity and its co-morbidities 
(Sun, Wu & Chau, 2016). Aspalathus linearis and Cyclopia species, more commonly known as 
rooibos and honeybush respectively, are indigenous South African plants that are widely consumed 
as herbal teas due to their pleasant aroma and taste (Joubert et al., 2008). Furthermore, these herbal 
teas are attracting increased interest due to their health promoting properties. Previous studies have 
shown that they are able to prevent the development of obesity (Dudhia et al., 2013; Pheiffer et 
al., 2013; Sanderson et al., 2014; Jack et al., 2017), insulin resistance (Mazibuko et al., 2013), T2D 
(Muller et al., 2012; Chellan et al., 2014) and CVD (Dludla et al., 2014). Moreover, a 
dihydrochalcone C-glycoside, Aspalathin, which is the main flavonoid of rooibos was shown to 
improve lipid metabolism in insulin resistant 3T3-L1 adipocytes (Mazibuko et al., 2015), while 
Mangiferin, a xanthone C- glycoside from honeybush was shown to ameliorate insulin resistance 
by inhibiting inflammation and regulating adipokine secretion in adipocytes cultured under 
hypoxic conditions (Yang et al., 2017). 
 
1.2 Problem statement 
Obesity is considered one of the greatest health challenges of the 21st century. Obesity increases 
the risk of developing chronic metabolic diseases such T2D, CVD and cancer, thereby significantly 
decreasing life expectancy (Peeters et al., 2003; Haslam & James, 2005). Effective interventions 
are required to reduce the burden of obesity on health systems, particularly those in LMIC that are 
already over-burdened and under-resourced and least able to respond to the escalating obesity 
crisis. Lifestyle modifications such as improved diet and physical activity are the most effective 
anti-obesity strategies (Lagerros & Rössner, 2013). However, these lifestyle modifications are 
difficult to adhere to, thus increasing reliance on therapeutics, which unfortunately are plagued by 
several side effects (Sweeting, Hocking & Markovic, 2015). There is an urgent need to identify 






In recent years, plant polyphenols have attracted increasing attention as nutraceuticals that are able 
to prevent or treat obesity and its co-morbidities. In particular, Aspalathus linearis, Cyclopia 
intermedia and their major polyphenol Aspalathin and Mangiferin, respectively have been shown 
to possess ameliorative properties against these conditions (Muller et al., 2012; Dudhia et al., 2013; 
Mazibuko et al., 2013; Pheiffer et al., 2013; Chellan et al., 2014; Dludla et al., 2014; Sanderson et 
al., 2014; Jack et al., 2017; Yang et al., 2017). The use of animal models to screen these compounds 
are restricted due to ethnical concerns, thus, in vitro experimental models are widely used as first-
line screening tools (Nilsson et al., 2012; Denayer, Stöhrn & Van Roy, 2014; Barrett, Mercer & 
Morgan, 2016). However, in vitro models do not reflect the complex pathophysiology of obesity 
(excess lipid accumulation, basal lipolysis, inflammation and oxidative stress) in vivo, which may 
hamper bioactivity testing (Ruiz-Ojeda et al., 2016; Langhans, 2018). It is therefore imperative to 
develop an in vitro model that mimics the pathophysiology of obesity in vivo (excess lipid 
accumulation, basal lipolysis, inflammation and oxidative stress) in order to improve the screening 
of anti-obesity therapeutics. 
 
1.4 Hypothesis 
1. We hypothesised that differentiating 3T3-L1 adipocytes in higher glucose concentrations for 
an extended period of time (compared to standard culture conditions) will exacerbate the co-
morbidities associated with obesity (increased lipid accumulation, basal lipolysis, oxidative 
stress and inflammation).  
2. Treatment with Aspalathus linearis, Cyclopia intermedia and their major polyphenols 
(Aspalathin and Mangiferin) will have ameliorative effects against increased lipid 









1.5 Aims  
The aims of this study are two-fold.  
• To develop a 3T3-L1 adipocyte in vitro model that more closely mimics obesity in vivo 
(increased lipid accumulation, basal lipolysis, oxidative stress and inflammation compared to 
standard conditions).  
• To assess the ameliorative effects of Aspalathus linearis, Cyclopia intermedia and their major 
polyphenol Aspalathin and Mangiferin, respectively, against increased lipid accumulation, 




Aim 1  
• To differentiate 3T3-L1 pre-adipocytes in 5.5 mM, 25 mM or 33 mM glucose concentrations 
for 7 or 14 days; and 
• To assess lipid accumulation, basal lipolysis, oxidative stress, inflammation, mitochondrial 
activity and gene expression. 
 
Aim 2 
• Acute and chronic treatment of the optimised model with Aspalathus linearis (Afriplex 
GRTTM), Cyclopia intermedia (CPEF) and their major compound Aspalathin and Mangiferin, 
respectively; and 
• To assess lipid accumulation, basal lipolysis, oxidative stress, inflammation, mitochondrial 

















2. Literature review 
2.1 Obesity definition 
The World Health Organisation (WHO) defines obesity as a complex metabolic disease 
characterised by the excessive accumulation of body fat to the extent that it negatively affects 
health (WHO, 2018). The body mass index (BMI) is the most commonly used method for assessing 
obesity; it is calculated by dividing an individual's weight in kilograms (kg) by the square of their 
height in meters (m) (kg/m2) (Nuttall, 2015). The WHO guidelines for the classification of obesity 
and metabolic risk are shown in Table 2.1 (WHO, 2000). However, the use of BMI to assess 
obesity is widely criticised. BMI is affected by gender and ethnicity and is not able to discriminate 
between muscle and fat mass. Methods that have been recommended as an alternative to BMI 
include waist circumference (WC), waist to hip ratio (WHR) and skinfold thickness (Kuriyan, 
2018; Osayande, Azekhumen & Obuzor, 2018; Eghan et al., 2019). Values of WC ≥ 88 cm for 
women and ≥ 102 cm for men are associated with a high metabolic risk (Table 2.1) (Kuriyan, 
2018). WHR measures the ratio of the WC to the hip circumference; ratios ≥ 0.80 for women and 
≥ 0.95 for men are associated with metabolic risk (Table 2.1). Skinfold thickness measures the 
thickness of subcutaneous tissue (skin layer) at sites such as the triceps, biceps or right hipbone 
with specialised callipers (Cornier et al., 2011; Kuriyan, 2018). More sensitive, but costly and 
technically challenging techniques due to their reliance on specialised equipment, include 
bioelectrical impedance analysis, computed tomography, dual-energy X-ray absorptiometry, 
magnetic resonance imaging and underwater weighing (Borga et al., 2018; Cornier et al., 2011; 








Table 2.1 Classification of obesity and metabolic risk 
 
 
Table taken from WHO, 2000.  
 
2.2 Epidemiology of obesity 
2.2.1 Global prevalence  
Globally, the prevalence of obesity has nearly tripled since 1975 (WHO, 2018). Recent estimates 
show that approximately 641 million individuals worldwide (8.9%) are obese, with the prevalence 
of obesity projected to reach 20% by 2025 (NCD-RisC, 2016). According to the WHO, 
approximately 41 million children under the age of five years were overweight or obese in 2016. 
The prevalence of overweight and obesity dramatically increased from 4% in 1975 to 18% in 2016 





2.2.2 Prevalence in South Africa 
Although obesity was historically associated with developed countries, in recent years, high rates 
of obesity are reported in LMIC (Ng et al., 2014; Ford, Patel & Narayan, 2017), thus placing a 
major burden on the already struggling and over-burdened health systems of these countries. 
Between 1980 and 2015, the prevalence of overweight and obesity has nearly doubled in Africa 
(Chooi, Ding & Magkos, 2019). South Africa, a middle-income country at the southernmost tip of 
Africa, has the highest rates of obesity in Africa. In 2013, approximately 69.3% of women older 
than 20 years were overweight, of whom 42% were obese. Although rates were lower in men 
(38.8% overweight and 13.5% obese), they are nevertheless higher than the global average (Ng et 
al., 2014). Similar trends were also observed in children and adolescents, with obesity rates of 
9.6% and 7.0% in girls and boys respectively. 
 
 
2.3 Risk factors for obesity 
Obesity is a multifactorial disease caused by a prolonged positive energy imbalance, resulting from 
increased energy intake and reduced energy expenditure (Hill, Wyatt & Peters, 2012). Obesity 
occurs due to the interplay of a number of factors including diet, physical activity, age, genetics 
and epigenetics (Figure 2.1), although the consumption of high calorie diets and the lack of 
physical activity are considered the main drivers of the current obesity pandemic (Hill, Wyatt & 
Peters, 2012). Furthermore, societal factors including socio-economic status and urbanisation have 
also contributed to the increased prevalence of obesity in developing countries (Micklesfield et al., 
2013). Other risk factors for obesity include medications such as antidepressants, glucocorticoids, 







Figure 2.1 Risk factors for obesity  
Overweight and obesity results from an energy imbalance due to the interplay of a multitude of risk factors.  
 
2.4 Adipose tissue  
Adipose tissue is a loose connective tissue that is mainly composed of adipocytes or fat cells, 
although other cell types present include fibroblasts, mesenchymal stem cells (MSCs), 
macrophages and vascular endothelial cells (Esteve Ràfols, 2014; Lynes & Tseng, 2018; Luong, 
Huang & Lee, 2019). Adipose tissue is widely distributed throughout the body and represents 15-
20% of body weight in normal-weight healthy men, and 25-30% in normal-weight healthy women 
(Gallagher et al., 2000). There are two types of adipose tissue, namely white adipose tissue (WAT) 
and brown adipose tissue (BAT), which vary according to location, cellular structure and 
physiological function (Saely, Geiger & Drexel, 2012; Lee, Mottillo & Granneman, 2014). 
 
2.4.1 White adipose tissue 
The WAT is the most common type of adipose tissue, composed of densely packed mature 
adipocytes (35-75%), pre-adipocytes, MSCs, T regulatory cells, endothelial precursor cells and 
macrophages (Esteve Ràfols, 2014; Lynes & Tseng, 2018; Luong, Huang & Lee, 2019). 
Adipocytes within WAT are spherical in morphology and contain a single large lipid droplet that 




periphery of the cytoplasmic area (Tandon, Wafer & Minchin, 2018). The main function of WAT 
is to regulate energy balance by storing excess energy as triacylglycerol and releasing energy in 
the form of FAs into the circulation when needed (Cinti, 2005; Church, Horowitz & Rodeheffer, 
2012). WAT expands by two mechanisms, namely hypertrophy which increases adipocyte size, or 
hyperplasia, which increases adipocyte number (Jo et al., 2009). Adipocyte hypertrophy is 
implicated in the pathogenic mechanisms underlying obesity (Figure 2.2) (Lee, Wu & Fried, 2010; 
Sun, Kusminski & Scherer, 2011; Kahn, Wang & Lee, 2019; Longo et al., 2019). Adipocyte 
hypertrophy leads to increased basal lipolysis and FA secretion, increased inflammation through 
secretion of MCP1 and pro-inflammatory macrophage infiltration, and increases ROS and 
oxidative stress, conditions implicated in the pathophysiological mechanisms of metabolic 
disorders (Figure 2.2) (Boden, 2011; Sun, Kusminski & Scherer, 2011; Jung & Choi, 2014; 
Boutens & Stienstra, 2016). Obesity increases the risk of T2D, CVD and several types of cancer 
(Haslam & James, 2005). Globally, overweight and obesity contributes to about 44%, 23% and 7–
41% of T2D, CVD and cancers, respectively (Frühbeck et al., 2013). Paradoxically, not all obese 
individuals develop chronic disease. Approximately 10-25% of obese individuals are 
metabolically healthy, while a similar percentage of normal weight individuals are metabolically 
unhealthy and have an increased risk of developing chronic disease (Blüher, 2010; Denis & Obin, 
2013; Smith, Mittendorfer & Klein, 2019). This suggests that fat distribution rather than fat mass 
define metabolic risk (Goossens, 2017; Kwon, Kim & Kim, 2017; Grundy, Williams & Vega, 
2018), and underscores the role of genetics and environmental factors in the development of 
obesity and metabolic disorders.  
 
Other than being a fat reservoir, WAT also functions as a cushion to protect vital organs against 
mechanical stress and acts as an insulator, which controls heat conduction through the skin (Zwick 
et al., 2018). Emerging evidence suggest that WAT is a major endocrine organ that plays a role in 
regulating whole-body metabolic homeostasis via the secretion of adipokines (Kershaw & Flier, 
2004; Coelho, Oliveira & Fernandes, 2013). These molecules play a vital role in regulating 
physiological processes such as appetite, energy balance, lipid and glucose metabolism and 
systemic immunity (Coelho, Oliveira & Fernandes, 2013; Musi & Guardado-Mendoza, 2014; 




(VAT) and subcutaneous adipose tissue (SAT) depots (Choe et al., 2016; Mittal, 2019). VAT is 
characterised by ectopic fat deposition around organs and is associated with higher metabolic risk. 
Several lines of evidence show that increased accumulation of VAT leads to impaired insulin 
action, increased inflammation and oxidative stress, and the development of metabolic disease 
(Alexopoulos, Katritsis & Raggi, 2014; Janochova, Haluzik & Buzga, 2019; Longo et al., 2019). 
Conversely, SAT is characterised by fat distribution in the femoral, hips and gluteal regions and is 
considered metabolically benign. SAT is a metabolic buffer that prevents lipotoxicity induced lipid 
overflow and ectopic fat accumulation in other tissues (Ibrahim, 2010). Inadequate SAT expansion 
leads to visceral and ectopic fat deposition, adipokine dysregulation and insulin resistance (Longo 
et al., 2019). 
 
2.4.2 Brown adipose tissue 
In contrast to WAT that functions as an energy reservoir, BAT induces non-shivering 
thermogenesis (Keipert & Jastroch, 2014; Jastroch, Oelkrug & Keipert, 2018). Adipocytes within 
BAT are smaller and contain many mitochondria with increased expression of mitochondrial 
uncoupling protein 1 (UCP1), which gives BAT its unique ability to generate heat via adaptive 
thermogenesis (Saely, Geiger & Drexel, 2012; Keipert & Jastroch, 2014; Lee, Mottillo & 
Granneman, 2014; Jastroch, Oelkrug & Keipert, 2018). BAT is mainly present in babies and 
decreases with age (Yoneshiro et al., 2011; Gonçalves et al., 2017; Zoico et al., 2019). Beige 
adipocytes are a relatively newly discovered adipocyte found interspersed within white adipocytes 
(Wu et al., 2012; Sepa-Kishi & Ceddia, 2018; Lizcano, 2019; Zoico et al., 2019). Under basal 
conditions, beige adipocytes are morphologically indistinguishable from white adipocytes, 
although they share similar functions with both white and brown adipocytes (Sepa-Kishi & Ceddia, 
2018). Beige adipocytes are activated upon cold exposure, chronic endurance exercise or β3-
adrenergic stimulation, and subsequently assume a brown adipocyte-like morphology with higher 
mitochondria content and multiple small lipid droplets (Sepa-Kishi & Ceddia, 2018). Activated 
beige adipocytes have higher expression of UCP1 and enhanced thermogenic capacity, thus leads 








Figure 2.2 Mechanisms relating adipocyte hypertrophy to metabolic disease 
Healthy adipose tissue is characterised by anti-inflammatory M2 macrophages. Factors such as 
unhealthy diets, physical inactivity, genetics and stress leads to adipocyte hypertrophy. 
Hypertrophied adipocytes recruit pro-inflammatory M1 macrophages, increasing inflammation 
and oxidative stress and impairing lipid metabolism. These conditions have systemic effects on 
peripheral tissues such as the heart, liver, muscle, pancreas and brain, leading to the development 
of chronic diseases. Arrow up (↑) indicates increase and arrow down (↓) signifies decrease. Figure 
taken and modified from (Jack et al., 2019).  
 
 
2.5 Obesity intervention 
Current intervention strategies for obesity include lifestyle modification, pharmacotherapy and 
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a Approved by FDA for long-term use. 
b Approved by FDA only for short term use (≤ 12 weeks) and low dose. 
c Only recommended for morbidly obese (BMI ≥ 40 kg/m2). 
Table abbreviations: β3-AR, beta-3 adrenergic receptor; ER, extended release; FDA, Food and 
Drug Administration; GLP-1, glucagon-like peptide 1; 5-HT2c, serotonin receptor; SR, sustained 





2.5.1 Lifestyle modification 
Lifestyle modifications such as calorie restriction and increased physical activity are the most 
effective first-line treatment strategies used in the management of overweight and obesity and have 
both been shown to induce significant weight loss (Table 2.2) (Fock & Khoo, 2013; Lagerros & 
Rössner, 2013). A low-calorie diet (800-1500 kcal/day) was shown to decrease bodyweight by 
10% in obese individuals over a period of 3-12 months, while a very low-calorie diet (≤ 800 
kcal/day) induced a 21.3% weight loss over a period of 6 months (Anderson, Luan & Høie, 2004; 
Fock & Khoo, 2013). A combination of diet and physical activity induced a 10.4% weight loss 
compared to diet (9.1%) or physical activity (2.1%) alone (Wing et al., 1998). However, studies 
have shown variability in an individual’s response to diet and exercise, which is most likely due 
to genetic variation (Bray, 2008). Furthermore, despite the success of lifestyle modification, 
adherence is poor, increasing reliance on pharmacological agents to manage obesity. 
  
2.5.2 Pharmacotherapy 
Pharmacotherapy is prescribed to individuals who are unable to control obesity with lifestyle 
modifications (Adan, 2013; Sweeting, Hocking & Markovic, 2015; Wharton, 2016; Patel & 
Stanford, 2018). Orlistat was approved by the Food and Drug Administration (FDA) for the long-
term treatment and management of obesity in 1990 and is the oldest anti-obesity drug on the market 
(Hvizdos & Markham, 1999; Sweeting, Hocking & Markovic, 2015; Patel & Stanford, 2018). It 
inhibits pancreatic lipase, thus decreasing intestinal fat absorption and promoting faecal fat 
excretion (Hvizdos & Markham, 1999). However, Orlistat has several gastrointestinal adverse 
effects such oily stools, flatulence, increased defaecation, while some studies have shown that 
Orlistat interferes with nutrient and drug absorption (Adan, 2013; Patel & Stanford, 2018). Other 
anti-obesity drugs, including Lorcaserin, Phentermine/topiramate, Naltrexone/buproprion and 
Liraglutide have been approved by the FDA over the past few years and are currently used for the 
long-term treatment and management of obesity, while Phentermine hydrochloride is approved by 
the FDA only for short term use and at low dose (Table 2.2) (Adan, 2013; Sweeting, Hocking & 
Markovic, 2015; Wharton, 2016; Patel & Stanford, 2018). Several new drugs or drug combination 
therapies that target the central nervous system, the gastrointestinal tract or adipose tissue 




promoting energy expenditure via thermogenesis) are currently under preclinical investigation or 
in clinical development and may be approved for obesity treatment in the next few years (Barja-
Fenández et al., 2014; Kakkar & Dahiya, 2015).  
 
2.5.3 Bariatric surgery 
Bariatric surgery, a collective term for gastrointestinal surgical procedures performed on severely 
obese patients who have at least one obesity-associated co-morbidity (Table 2.2), is considered the 
most effective treatment for reducing excess body weight (Kissler & Settmacher, 2013; Piché et 
al., 2015; Wolfe, Kvach & Eckel, 2016). The currently established bariatric procedures include the 
sleeve gastrectomy, adjustable gastric band, laparoscopic Roux-en-Y gastric bypass, and 
biliopancreatic diversion with duodenal switch (Table 2.2) (Kissler & Settmacher, 2013; Piché et 
al., 2015; Wolfe, Kvach & Eckel, 2016). These surgical procedures restrict food intake and reduce 
nutrient absorption by decreasing stomach size or changing the anatomy of the gastrointestinal 
area, thus suppressing appetite and improving weight loss and metabolic status (Table 2.2) (Kissler 
& Settmacher, 2013; Piché et al., 2015; Wolfe, Kvach & Eckel, 2016). Despite the beneficial 
effects of bariatric surgery, these surgical procedures are expensive and are associated with post-
surgery complications such as the malabsorption of essential vitamins, minerals and 
pharmacological drugs (Kassir et al., 2016).  
 
2.6 Natural products as anti-obesity agents 
Plant-derived natural products are attracting increasing interest as therapeutic agents due to the 
perception that they are safer and more cost-effective than synthetic drugs (Mopuri & Islam, 2017; 
Jack et al., 2019). Natural products from different sources, especially from plants, have been used 
as remedies for human diseases for centuries and offer potential as a source for the development 
of new drugs (Veeresham, 2012; Mushtaq et al., 2018). Polyphenols are secondary plant 
metabolites with a variety of beneficial health effects (Pandey & Rizvi, 2009). They are found in 
a variety of dietary sources including fruits, vegetables and beverages such as tea or wine and are 
widely explored as an alternative or as an adjunct to conventional obesity treatment (Manach et 




(rooibos) and Cyclopia ssp. (honeybush) are endemic South African plants consumed as herbal 
teas globally. These teas are caffeine-free and have a low tannin content (Joubert et al., 2008; 
Stander, Joubert & De Beer, 2019). Over the last few years, the global demand for these teas has 
increased and is partly attributed to their perceived beneficial health properties (Muller et al., 2018; 
Joubert et al., 2019). Likewise, studies have reported that the major phenolic compounds present 
in rooibos and honeybush possess anti-obesity effects (Fomenko & Chi, 2016; Johnson et al., 2018; 
Jack et al., 2019).  
 
2.6.1 Aspalathus linearis 
Aspalathus linearis (Brum.f) Dahlg. (Fabaceae), commonly known as rooibos, is a shrub-like 
leguminous member of the fynbos biome indigenous to the Western and Northern Cape region of 
South Africa (Joubert et al., 2008; Joubert & de Beer, 2011). Rooibos is consumed as a 
“fermented” (oxidised) or “unfermented” (green) rooibos tea (Joubert & de Beer, 2011). During 
fermentation, the leaves and stems of the rooibos plant material are bruised and soaked to enhance 
the natural oxidation process, which gives rise to a rooibos infusion with a distinctive reddish-
brown colour and a pleasant, slightly sweet flavour. Unfermented rooibos tea maintains its green 
colour due to limited oxidation (Joubert et al., 2008; Joubert & de Beer, 2011).  
 
Unlike the fermented rooibos, which has reduced anti-oxidant content as a result of oxidation, the 
unfermented rooibos product preserves the quality of anti-oxidants and polyphenols such as 
Aspalathin (Marnewick et al., 2005; Villaño et al., 2010; Joubert & de Beer, 2011). Unfermented 
rooibos tea displays a 28% higher in vitro anti-oxidant capacity than fermented rooibos tea 
(Villaño et al., 2010). Aspalathin, a C-glucosyl dihydrochalcone unique to rooibos (Figure 2.3), is 
considered the major biological active polyphenol in rooibos (Joubert & de Beer, 2011). Other 
major bioactive compounds found in rooibos include the dihydrochalcone, Nothofagin, flavones 
(Orientin, Isoorientin, Luteolin, and Apigenin) and the flavonols (Quercetin and Rutin) (Joubert & 
de Beer, 2011). Phenylpyruvic acid-2-O-β-D-glucoside (PPAG) is one of the major constituents of 







Figure 2.3 Chemical structure of Aspalathin 
Chemical structure obtained from ChemSpider database (http://www.chemspider.com, 2019a). 
 
In addition to its widely reported anti-oxidant properties (Joubert et al., 2005; Villaño et al., 2010), 
many studies have reported that rooibos tea has anti-mutagenic (Marnewick, Gelderblom & 
Joubert, 2000; Standley et al., 2001), anti-cancer (Marnewick et al., 2005), anti-inflammatory 
(Baba et al., 2009), cardioprotective (Pantsi et al., 2011; Dludla et al., 2014), anti-diabetic (Muller 
et al., 2012; Mazibuko et al., 2013; Kamakura et al., 2015; Sasaki, Nishida & Shimada, 2018), and 
anti-obesity (Beltrán-Debón et al., 2011; Sanderson et al., 2014) properties. Sanderson et al. 
showed that rooibos inhibits adipogenesis and intracellular lipid accumulation in 3T3-L1 
adipocytes, accompanied by decreased expression of adipogenesis and lipid accumulation genes 
and proteins (Sanderson et al., 2014). Although the anti-obesity effects of Aspalathin have not 
been reported yet, this compound was shown to improve glucose and lipid metabolism in insulin 
resistant 3T3-L1 adipocytes (Mazibuko et al., 2015). Recently, a green rooibos extract (GRT) was 
manufactured by Afriplex (Paarl, Western Cape, SA) according to standardised conditions. The 
polyphenol content is enriched as the rooibos is not fermented (Figure 2.4). GRT was shown to 
have beneficial health effects against hyperglycaemia, oxidative stress and dyslipidaemia in high-






Figure 2.4 Chemical composition of Aspalathus linearis (Afriplex GRT) 
Figure shows high performance liquid chromatography (HPLC) chromatograms of the GRT 
extract (A) with compound content values presented in g/100g extract (B). Adapted and modified 
from (Patel et al., 2016). 
 
 
2.6.2 Cyclopia spp.  
Cyclopia spp. (Genus: Cyclopia Vent.; Family: Fabaceae; Tribe: Podalrieae) are indigenous South 
African plants that are used to produce honeybush tea (Joubert et al., 2011, 2019). Twenty-three 
species of Cyclopia have been described thus far, with six species (C. subternata, C. genistoides, 
C. intermedia, C. maculata, C. longifolia and C. sessiliflora) used for commercial tea production 
(Joubert et al., 2011). Over the past 20 years, the honeybush tea industry has gained increased 
popularity, mainly due to its distinctively sweet flavour and aroma (Joubert et al., 2019). Plant 
material is fermented or oxidised at a high temperature to give the distinctive characteristics of 
honeybush tea. In recent years, unfermented or green honeybush has attracted interest due to its 





Cyclopia spp. are a rich source of complex bioactive phenolic compounds, and high quantities of 
the xanthones, Mangiferin (Figure 2.5) and its isomer, Isomangiferin, the flavanone, Hesperidin, 
the benzophenone glucosides (3-β-D-glucopyranosyliriflophenone, 3-β-D-glucopyranosyl-4-β-D-
glucopyranosyloxyiriflophenone and 3-β-D-glucopyranosylmaclurin), as well as dihydrochalcone 
glycosides (Phloretin-3′,5′-di-C-β-D-glucoside and 3-hydroxy-phloretin-3′,5′-di-C-hexoside) have 
been detected in extracts of several Cyclopia plants (Jack et al., 2019; Joubert et al., 2019). Other 
phenolic compounds found in Cyclopia spp. include the flavanones (Hesperitin, Naringenin, 
Eriocitrin, Neoponcirin and Eriodictyol) and flavones (Luteolin, Scolymoside and Vicenin-2), 
which have been detected in relatively small amounts in extracts of several Cyclopia plants (Jack 





Figure 2.5 Chemical structure of Mangiferin 
Chemical structure obtained from ChemSpider database (http://www.chemspider.com, 2019b). 
 
Cyclopia spp. exhibit potential anti-obesity (Dudhia et al., 2013; Pheiffer et al., 2013; Jack et al., 
2017, 2018), anti-diabetic (Muller et al., 2011; Chellan et al., 2014), anti-oxidant (Joubert et al., 
2008; Lawal, Davids & Marnewick, 2019), anti-mutagenic (van der Merwe et al., 2006), anti-
cancer (Marnewick et al., 2005), phytoestrogenic (Mortimer et al., 2015), anti-osteoclastogenic 
(Visagie et al., 2015), anti-allergic (Murakami et al., 2018) and anti-inflammatory (Lawal, Davids 




enriched organic fraction of C. intermedia (CPEF) possesses anti-obesity effects in vitro and in 
vivo (Jack et al., 2017). The polyphenolic profile and compounds within CPEF are shown in Figure 
2.6. Several studies have reported that Mangiferin, the major polyphenol detected within Cyclopia 
spp. (Figures 2.5 and 2.6), possesses anti-obesity properties in vitro in adipocyte models 
(Yoshikawa et al., 2002; Subash-Babu & Alshatwi, 2015; Yang et al., 2017). In vivo studies 
revealed that Mangiferin can reduce body weight and ameliorate obesity-associated metabolic 
conditions (Guo et al., 2011; Niu et al., 2012; Apontes et al., 2014; Lim et al., 2014; Acevedo et 




Figure 2.6 Chemical composition of Cyclopia intermedia (CPEF) 
Figure shows a HPLC chromatogram of CPEF (A) with compound content values presented in 









2.7 Experimental models 
Development of anti-obesity therapeutics require extensive preclinical screening which makes use 
of in vivo animal models and in vitro cell culture models.  
 
2.7.1 In vivo models 
Animal models have played a key role in elucidating the aetiology of obesity, including the 
physiological processes and genetic mechanisms that regulate energy homeostasis, appetite and 
adipose tissue metabolism (Agahi & Murphy, 2014; Barrett, Mercer & Morgan, 2016). In vivo 
models such as rodents and non-human primates have been used to better elucidate the efficacy, 
safety, pharmacology and pharmacokinetic potential of anti-obesity drug candidates before testing 
in humans (Agahi & Murphy, 2014). The currently used animal models of obesity include diet-
induced obese (DIO) animal models and genetic models (Barrett, Mercer & Morgan, 2016). The 
DIO animal model involves feeding animals a diet that is high in fat, sucrose or fructose (or the 
combination) to induce obesity and several glucose and lipid metabolic abnormalities. As such, 
DIO models have been used to develop anti-obesity drugs because they provide a better 
understanding of the pathophysiology of obesity, especially the gene–environment interactions 
underlying the major causes of human obesity (Barrett, Mercer & Morgan, 2016; Ohta, Murai & 
Yamada, 2017). Genetic models have a spontaneous mutation or are genetically engineered to 
express certain physiological traits such as extreme obesity. They have been used to provide 
valuable insight into the pathophysiological contribution of particular genes to obesity (Agahi & 
Murphy, 2014; Barrett, Mercer & Morgan, 2016). The use of animal models for screening anti-
obesity drugs is restricted due to ethical concerns and legislations including the “Three Rs” 
(reduction, refinement, and replacement) (Sharma et al., 2011; Pasupuleti, Molahally & Salwaji, 
2016). As a result, in vitro models are commonly used as an alternative first line screening tool.  
 
2.7.2 In vitro models 
In vitro models such as immortalized cell lines are used as an alternative to in vivo animal testing 
in biomedical research (Chacon et al., 1996, Romero et al., 2014). These in vitro models are 




understand their effects on cellular physiology and metabolism, dose response and toxicity effects 
(Astashkina, Mann & Grainger, 2012; Ruiz-Ojeda et al., 2016). In addition, in vitro models are 
useful for rapid and inexpensive screening of bioactive compounds in a controlled environment 
(temperature, pH, hormone and nutrient concentrations, etc.), thus reducing experimental 
variation. Cell lines provide homogeneous, genetically identical cellular populations and cell types 
which are at the same differentiation stage, therefore, allowing a homogeneous response to 
treatments and providing consistent and reproducible results (Carter & Shieh 2010). However, cell 
lines have altered characteristics and functions compared to their in vivo counterparts.  
 
In vitro models such as 3T3-L1 and 3T3F442A cells are the most commonly used adipocyte 
models for obesity studies (Ruiz-Ojeda et al., 2016). In this study we used the 3T3-L1 cell line, a 
well-established pre-adipocyte cell line derived from murine swiss 3T3 mouse embryos (Green & 
Meuth, 1974). 3T3-L1 cells exhibit a fibroblast-like morphology and upon stimulation with 
adipocyte differentiation inducers (insulin, dexamethasone and 3-isobutyl 1-methylxanthine 
(IBMX)), are converted to mature adipocytes (Green & Meuth, 1974; Green & Kehinde, 1975). 
Although mature 3T3-L1 adipocytes exhibit the physiological characteristics and molecular 
mechanisms of adipocytes in vivo, there have been concerns about how closely they mimic the 
pathophysiology of obesity and its associated morbidities (oxidative stress, mitochondrial 
dysfunction, inflammation, etc.) in vivo. Therefore, it is imperative to develop a 3T3-L1 adipocyte 
model that closely mimics the pathophysiology of obesity in order to allow the screening and 
















3. Materials and methods 
3.1 Study design 
The experimental overview is illustrated in Figure 3.1. Firstly, to develop a model of increased 
lipid accumulation, basal lipolysis, oxidative stress and inflammation, 3T3-L1 pre-adipocytes were 
differentiated in 5.5 mM, 25 mM or 33 mM glucose concentrations for 7 or 14 days. Lipid 
accumulation, basal lipolysis, oxidative stress and inflammation were assessed using Oil Red O 
(ORO) staining, glycerol release, cytokine secretion (tumour necrosis factor-alpha (TNFα), MCP1 
and interleukin-6 (IL6)) and quantifying ROS using the 2',7'-dichlorfluorescein-diacetate (DCFH-
DA) fluorescent dye, respectively. In addition, mitochondrial dehydrogenase activity was assessed 
using the 3- [4, 5-Dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide (MTT) assay, and the 
expression of genes associated with lipid accumulation, basal lipolysis, inflammation and 
oxidative stress were measured using quantitative real-time polymerase chain reaction (qRT-
PCR). 
 
Secondly, the anti-obesity effects of two plant extracts and their major polyphenols were assessed 
by investigating their ameliorative properties against lipid accumulation, basal lipolysis, oxidative 
stress and inflammation in the optimised experimental model developed previously. Briefly, 3T3-
L1 adipocytes were treated with a standardised green rooibos extract of Aspalathus linearis (GRT), 
a crude polyphenol enriched fraction of Cyclopia intermedia (CPEF) and their major compound 
Aspalathin and Mangiferin, respectively. The treatment was divided into acute and chronic 







Figure 3.1 Experimental overview 
 
3.2 Materials 
The murine 3T3-L1 pre-adipocyte cell line (ATCC® CL-173™) was purchased from the American 
Type Culture Collection (ATCC), Manassas, VA, USA. GRT, a standardised, commercial extract 
of Aspalathus linearis containing 12.8% of Aspalathin was obtained from Afriplex (Pty) Ltd., 
Paarl, Western Cape, SA. The CPEF was supplied by Babalwa Jack (Jack et al., 2017). Aspalathin 
(ca. 98% purity) was purchased from High Force Research Ltd., Durham, UK. Mangiferin (≥ 98% 
purity) was purchased from Sigma-Aldrich, St Louis, MO, USA and Isoproterenol was purchased 
from Merck (Sigma-Aldrich, St Louis, MO, USA). All other chemicals were purchased from 
Sigma-Aldrich, St Louis, MO, USA, unless otherwise stated. All materials, suppliers and product 





3.3 Cell culture 
Cell culture was conducted adhering to aseptic technique (Appendix). The 3T3-L1 pre-adipocytes 
were cultured and maintained in Dulbecco’s modified eagle media (DMEM, Gibco, Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with 25 mM glucose and 10% fetal bovine serum 
(FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) (standard conditions for 3T3-L1 
culture recommended by the ATCC) (ATCC, 2013), or in 5.5 mM, 25 mM, or 33 mM glucose and 
10% FBS for experimental conditions. Cell culture procedures were conducted in a biohazard 
safety cabinet, class II (Airvolution lab, Johannesburg, Gauteng, SA) and cells were maintained in 
an incubator (Galaxy R CO2 incubator, RS Biotech, West Lothian, UK) at 37°C in humidified air 
with 5% carbon dioxide (CO2) (Air Products, Bellville, Western Cape, SA). 
 
3.3.1 Thawing and culturing of 3T3-L1 cells 
A cryogenic vial containing 3T3-L1 cells (1×106 cells/ml) in cryopreserving medium containing 
DMEM, 10% FBS and 7% (v/v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO, 
USA) was removed from liquid nitrogen storage and thawed in a 37°C water bath. Immediately 
after thawing, the cells were transferred into a 15 ml centrifuge tube containing 9 ml of 37°C pre-
warmed, pre-adipocyte growth medium (DMEM supplemented with 10% FBS) and centrifuged at 
800 × g for 5 min (Eppendorf 5810 Centrifuge, Eppendorf, Hamburg, Germany). Thereafter, the 
supernatant was aspirated, and the cell pellet was resuspended in 5 ml of pre-warmed, pre-
adipocyte growth medium. Following this, 1 ml of cell suspension was transferred to a 75 cm2 
tissue culture flask (T75) (Nest Scientific, Rahway, NJ, USA) containing 17 ml of pre-warmed, 
pre-adipocyte growth medium. The cells were incubated under standard cell culture conditions 
(37°C in humidified air with 5% CO2) for 24 hrs, where after the pre-adipocyte growth medium 
was refreshed. Cells were kept under standard cell culture conditions until they reached 70-80% 
confluency and subsequently sub-cultured using a split ratio of 1:5 (section 3.3.2). Passage number 
was kept to below 20 in order to prevent the depletion of specific cell phenotypes such as the 






3.3.2 Sub-culture of 3T3-L1 cells 
3.3.2.1 Trypsin treatment 
Upon confluency, pre-adipocyte growth medium was aspirated from the T75 flask, (Nest 
Scientific, Rahway, NJ, USA) and cells were rinsed with pre-warmed Dulbecco’s phosphate 
buffered saline (DPBS) (Lonza, Walkersville, MD, USA). Thereafter, the adherent cells were 
dislodged by incubating with 2 ml of trypsin (Lonza, Walkersville, MD, USA) under standard cell 
culture conditions for 5 - 7 min. Cells were viewed under an Olympus inverted light microscope 
(CKX 41, Olympus; Melville, NY, USA) to confirm whether they had dislodged from the flask. 
Trypsinisation was stopped by adding 8 ml of pre-warmed pre-adipocyte growth medium directly 
to the cells, where after the cell suspension was thoroughly mixed by gently pipetting up and down 
at least 8 times to disaggregate cell clumps and ensure a single cell suspension. Thereafter, the cell 
suspension was transferred to a 15 ml centrifuge tube and centrifuged for 5 min at 800 × g 
(Eppendorf 5810 Centrifuge, Eppendorf, Hamburg, Germany). The supernatant was aspirated, and 
the cell pellet was resuspended in pre-warmed, pre-adipocyte growth medium, subsequently sub-
cultured in T75 flasks and incubated under standard cell culture conditions. Cell density and 
viability were determined (section 3.3.2.2) prior to freezing cells for storage (section 3.3.2.3) or 
seeding cells in their appropriate multi-well plates for subsequent in vitro bioassays (section 
3.3.2.4). 
 
3.3.2.2 Cell counting  
Following trypsinisation, the number of viable cells were quantified using a haemocytometer and 
trypan blue dye (Invitrogen, Carlsbad, CA, USA). Briefly, a 10 μl volume containing the cell 
suspension and trypan blue in a 1:1 ratio was loaded onto one of the haemocytometer chambers 
(Figure 3.2B) and viewed under an inverted microscope where both viable (clear/unstained) and 
non-viable (stained blue) cells were counted in four of the nine quadrants of the haemocytometer 
(Figure 3.2C). The percentage of viable cells was calculated using the formula in Figure 3.2A. If 
the viability of cells was 70% or above, they were used for making stocks for freezing or seeded 







Figure 3.2 Cell counting 
Equation for determining cell viability (A), an illustration showing the haemocytometer slide with 
two counting chambers (B) and the number of squares used for cell counting (indicated by grey 
circled numbers) to obtain number of cells/ml (C). Cells on the bottom and right lines of the 
quadrant were not counted. 
 
3.3.2.3 Freezing 3T3-L1 pre-adipocytes 
Subsequent to cell counting, cells were centrifuged at 800 × g for 5 min. The supernatant was 
carefully discarded without disturbing the pellet, and the pellet was resuspended in sterile cold 
freezing medium containing DMEM, 10% FBS and 7% (v/v) DMSO at a volume required to 
achieve 1 × 106 cells/ml. The resuspended cell suspension was aliquoted into cryotubes (1 ml) and 
placed on ice. Each cryovial was labelled with the cell line, passage number, cell concentration 






3.3.2.4 Seeding of 3T3-L1 pre-adipocytes  
After quantifying the number of viable cells, 3T3-L1 pre-adipocytes were seeded at relative 
seeding densities into their respective multi-well plates (Table 3.1). The seeding cell concentration 
for 3T3-L1 pre-adipocytes is 2 × 104 cells/ml. Thereafter, the cells were incubated under standard 
cell culture conditions in pre-adipocyte growth medium, until they reached 100% confluency (~4 
days) and the medium was refreshed every 48 hrs.  
 









96-well 2 × 104 4 × 103 0.2 ml 
24-well 2 × 104 2 × 104 1 ml 
6-well 2 × 104 6 × 104 3 ml 
 
 
3.3.3 3T3-L1 pre-adipocyte differentiation 
Adipocyte differentiation was conducted in accordance with the ATCC protocol (ATCC, 2013), 
with slight modifications in order to develop an in vitro 3T3-L1 adipocyte model with increased 
lipid accumulation, basal, oxidative stress and inflammation. Briefly, fully confluent 3T3-L1 pre-
adipocytes (100% confluent at day 4 post seeding) were induced to differentiate into adipocytes 
by incubating the cells (day 0) in adipocyte differentiation medium (ADM) consisting of DMEM, 
at various concentrations of glucose (5.5 mM, 25 mM and 33 mM) each supplemented with 10% 
FBS, 0.5 mM IBMX (Sigma-Aldrich, St Louis, MO, USA), 1 µg/ml insulin (Sigma-Aldrich, St 
Louis, MO, USA) and 1 μM dexamethasone (Sigma-Aldrich, St Louis, MO, USA ) under standard 
cell culture conditions until day 3 of differentiation (Figure 3.3). After 72 hrs (day 3), the ADM 
was changed to adipocyte maintenance medium (AMM) consisting of DMEM, at various 
concentrations of glucose (5.5 mM, 25 mM and 33 mM) each supplemented with 10% FBS and 1 




(5.5 mM, 25 mM or 33 mM glucose concentrations) supplemented with 10% FBS under standard 
cell culture conditions until day 7 or day 14 of differentiation, with medium refreshed every 48 hrs 
(Figure 3.3). The cells and the cell culture media were collected at days 0, 7 and 14 of 
differentiation, and used for bioassays and gene expression analysis as shown in Figure 3.3. 
 
3.3.4 Cell culture media collection  
After the 3T3-L1 cells were differentiated or treated as described in sections 3.3.3 and 3.3.5, cell 
culture media were collected into 15 ml centrifuge tubes (Nest Scientific, Rahway, NJ, USA). The 
collected media were centrifuged (SL 16R Thermo Fisher Scientific, Waltham, MA, USA) at 3 
500 × g for 15 min at 4°C to remove cell debris. Thereafter, the media were aliquoted and stored 










3.3.5 Treatment with GRT, CPEF, Aspalathin and Mangiferin 
3.3.5.1 Preparation of extracts and compounds  
The GRT and CPEF extracts were each weighed and prepared fresh daily by dissolving in 10% 
DMSO to yield a stock concentration of 10 mg/ml. The compounds, Aspalathin (452.13 g/mol) 
and Mangiferin (422.34 g/mol) were both weighed (20 mg) and dissolved in 2 ml of 100% DMSO 
to yield stock solutions of 22.1 mM and 23.6 mM, respectively. Stock solutions of compounds 
were aliquoted into 2 ml Eppendorf tubes and stored at -80⁰C until required. Thereafter, stock 
solutions of 1 mg/ml GRT, 1 mg/ml CPEF, 22.1 mM Aspalathin and 23.6 mM Mangiferin were 
prepared in treatment medium (either DMEM supplemented with 33 mM glucose and 10% FBS 
or DMEM without phenol red supplemented with 33 mM glucose, 0.1% bovine serum albumin 
(BSA) and 3.7 g/l sodium bicarbonate (NaHCO3) (Sigma-Aldrich, St Louis, MO, USA)). Stock 
solutions were serially diluted 10-fold to prepare 0.1, 1, 10 and 100 µg/ml or 0.1, 1, 10 and 100 
µM working solutions in their respective treatment media. The highest working solution (100 
µg/ml or 100 µM) was filter sterilised using a 0.22 μM pore-size Millex-GP Polyethersulfone 
membrane syringe filter before subsequent dilutions were prepared. The final concentration of 
DMSO in the working solutions was 0.01% (v/v) DMSO, thus 0.01% (v/v) DMSO prepared in 
treatment medium was used as a vehicle control since it was previously shown not to affect cell 
viability and lipid content in 3T3-L1 adipocytes (Dludla et al., 2018). A 10 μM concentration of 
Isoproterenol, a selective β-adrenergic receptor agonist that induces lipolysis (Schott et al., 2017), 
was added to the cells as a positive control. Cells were treated as described below (sections 3.3.5.2 
and 3.3.5.3). 
 
3.3.5.2 Chronic treatment 
For chronic treatment, 3T3-L1 pre-adipocytes were seeded into 24-well plates and differentiated 
in 33 mM glucose media until day 7, as described in section 3.3.3. At day 7, 3T3-L1 adipocytes 
were treated with 33 mM glucose media, a vehicle control (0.01% DMSO), GRT, CPEF, 
Aspalathin, Mangiferin or Isoproterenol for 6 days, and treatment media was refreshed every 48 
hrs. At day 13, the treatment media was replaced with DMEM without phenol red media and 




3.3.5.3 Acute treatment 
For acute treatment, 3T3-L1 pre-adipocytes were seeded in 24-well plates and differentiated in 33 
mM glucose for 14 days as described in section 3.3.3. On day 14, differentiated 3T3-L1 adipocytes 
were treated for 24 hrs with 33 mM glucose medium, a vehicle control, the GRT, CPEF, Aspalathin 





Figure 3.4 Treatment experimental outline 






3.4 The 3- [4, 5-dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide assay 
Cell viability was assessed using the MTT assay, a quantitative colorimetric assay that measures 
cell survival and proliferation. The MTT assay measures the reduction of the yellow tetrazolium 
salt (MTT) to a purple formazan product by mitochondrial succinate dehydrogenase activity 
(Mosmann, 1983; Weyermann, Lochmann & Zimmer, 2005), a process which indicates 
metabolically viable cells. After the 3T3-L1 cells were differentiated or treated as described 
previously (sections 3.3.3 and 3.3.5), the medium was aspirated, and cells were washed with pre-
warmed DPBS. Afterwards, 50 μl of pre-warmed MTT (Sigma-Aldrich, St Louis, MO, USA) 
solution (2 mg/ml prepared in DPBS) was added to the cells and incubated at 37°C under standard 
cell culture conditions for 30 min. After incubation, the MTT solution was aspirated, 200 μl of 
DMSO and 25 μl of Sorenson’s glycine buffer (0.1 M Glycine and 0.1 M Sodium chloride, pH 
10.5) were added to each well, and the plate was gently shaken to dissolve the purple formazan 
crystals. Absorbance was measured at 570 nm using the BioTek® ELx800 plate reader and the Gen 
5 software (BioTek Instruments Inc., Winooski, VA, USA). Absorbance values were used to 
quantify MTT content and results were expressed as a percentage relative to the control at 100%. 
 
3.5 Oil red o assay 
The accumulation of lipid droplets was measured using ORO staining. ORO is a hydrophobic fat-
soluble dye that stains and quantifies neutral intracellular lipids red (Escorcia et al., 2018). After 
the 3T3-L1 cells were differentiated or treated as described previously (sections 3.3.3 and 3.3.5), 
the medium was aspirated, cells were washed with pre-warmed DPBS and thereafter fixed with 
10% (v/v) neutral buffered formalin for 15 min at room temperature. Cells were rinsed with DPBS 
and stained with 0.7% (v/v) ORO (Sigma-Aldrich, St Louis, MO, USA) working solution 
(prepared by diluting a 1% stock (w/v) in 100% Isopropanol (Sigma-Aldrich, St Louis, MO, USA) 
with distilled water) for 30 min at room temperature. Subsequently, ORO stain was removed, and 
cells were rinsed with distilled water at least three times to remove the unbound stain. Thereafter, 
the amount of lipid accumulation in cells was quantified by dissolving the dye that was retained in 
the cells with 200 µl of 100% Isopropanol, after which absorbance was read at 490 nm using a 
BioTek® ELx800 plate reader equipped with Gen 5® software (BioTek Instruments Inc., Winooski, 




Lipid content was normalised to cell density using crystal violet (CV) staining that stains live cells 
(Chiba, Kawakami & Tohyama, 1998). Briefly, after extraction of the ORO stain, cells were 
washed with 70% (v/v) ethanol (Sigma-Aldrich, St Louis, MO, USA), and thereafter stained with 
CV solution (0.5% v/v) prepared by diluting a 1% (w/v) stock with distilled water. Following 5 
min of incubation at room temperature, the CV dye was removed, cells were washed three times 
with DPBS, and cell density was quantified by eluting the CV dye retained in the cells with 70% 
(v/v) ethanol. Absorbance was measured at 570 nm using a BioTek® ELx800 plate reader equipped 
with Gen 5® software (BioTek Instruments Inc., Winooski, USA) for data acquisition. The 
ORO/CV values were calculated and expressed as a percentage relative to the control.  
 
3.6 Glycerol release assay 
Lipolysis was assessed by measuring the glycerol secreted in the cell culture media. Lipolysis is 
the process whereby triglycerides are broken down to FAs and glycerol, and the dysregulation of 
lipolysis is associated with adipose tissue dysfunction and obesity (Gaidhu et al., 2010). Thus, the 
quantification of glycerol is used as a marker for lipolysis. After 3T3-L1 cells were differentiated 
or treated as described previously (sections 3.3.3 and 3.3.5), glycerol secreted into cell culture 
media was quantified using the Lipolysis Colorimetric Assay Kit (Sigma-Aldrich, St Louis, MO, 
USA) according to the manufacturer’s instructions. Briefly, a glycerol standard curve was prepared 
by pipetting 0, 2, 4, 6, 8, and 10 μl (in duplicate) of a 1 mM glycerol standard into a clear 96-well 
plate, where after glycerol assay buffer was added into each well to a final volume of 50 μl. For 
each sample, 50 μl of the undiluted cell culture medium was added to the 96 well plate, in duplicate, 
and thereafter, 50 μl of a reaction mix consisting of 46 μl of glycerol assay buffer, 2 μl of glycerol 
probe and 2 μl of glycerol enzyme mix was added to both sample and standard wells. The plate 
was incubated for 30 min at room temperature, protected from light. After incubation, absorbance 
was measured at 570 nm using a SpectraMax® i3x Multi-Mode Microplate reader and the SoftMax 
Pro 7 Software (Molecular Devices, Sunnyvale, CA, USA). The glycerol concentration for each 





3.7 The 2',7'-dichlorfluorescein-diacetate (DCFH-DA) fluorescent assay  
Intracellular production of ROS, a marker of oxidative stress, was measured using the 2',7'-
dichlorfluorescein-diacetate (DCFH-DA) fluorescent dye as previously described (Dludla et al., 
2018). The method is based on the oxidation of the non-fluorescent fluorescein derivative (DCFH-
DA) by ROS to yield a highly fluorescent product, 2',7'-dichlorofluorescein (DCF). After 3T3-L1 
cells were differentiated as described in section 3.3.3, cells were rinsed with Hank’s Balanced Salt 
Solution (HBSS, Lonza, Walkersville, MD, USA) followed by incubation with 1 µM of DCFH-
DA (Biolabs, Inc., San Diego, CA, USA) (prepared in HBSS) for 30 min, under standard cell 
culture conditions. The cells were washed once with 100 µl of HBSS, thereafter, the same volume 
of HBSS was added in each well to measure DCF fluorescence signal at an excitation/emission 
spectrum of 485 ± 20 and 528 ± 20 nm using a BioTek® FLx800 plate reader and Gen 5 software 
(BioTek Instruments Inc., Winooski, USA). 
 
3.8 Enzyme-linked immunosorbent assay (ELISA)  
Inflammation was quantified by measuring the amount of MCP1 secretion. MCP1 is a potent 
chemoattractant for macrophage infiltration and activation in adipose tissue and induces 
inflammation in adipocytes (Kanda et al., 2006). After 3T3-L1 cells were differentiated or treated 
as described previously (sections 3.3.3), MCP1 secretion was quantified in cell culture 
supernatants using the mouse MCP1 DuoSet ELISA Kit (R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer’s instructions. Briefly, a 96-well microplate was coated with 100 μl 
per well of capture antibody diluted with phosphate buffered saline (PBS) and incubated at room 
temperature overnight (~16 hrs). The following day, each well was aspirated and washed 3 times 
by filling with wash buffer (400 μl) using a squirt bottle. For good performance, after the last wash 
the plate was blotted against clean paper towel to completely remove wash buffer residue. The 
plate was blocked by adding 300 μl of reagent diluent to each well, sealed and incubated at room 
temperature for a minimum of 1 hr. Thereafter, each well was aspirated and washed 3 times as 
previously described. Hereafter, 100 μl of samples or standards (250, 125, 62.5, 31.3. 15.6, 7.8, 
3.9 pg/ml) were added to the plate in duplicate. The plate was sealed with an adhesive strip and 
incubated for 2 hrs at room temperature. The wells were aspirated and washed with wash buffer 




was added into each well and the plate was sealed with a new adhesive strip and incubated for 2 
hrs at room temperature. Each well was aspirated and washed with wash buffer as previously 
described. After adding 100 μl of streptavidin horseradish peroxidase (HRP) working dilution to 
each well, the plate was sealed and incubated away from light for 20 min at room temperature. The 
wells were aspirated and washed 3 times with wash buffer as previously described. Thereafter, 100 
μl of substrate solution was added to each well and incubated for 20 min at room temperature 
avoiding direct light. The reaction was stopped by adding 50 μl of stop solution to each well. The 
plate was mixed by tapping it gently. Finally, absorbance was measured at 450 nm on a 
SpectraMax® i3x Multi-Mode Microplate reader using the SoftMax Pro 7 Software (Molecular 
Devices, Sunnyvale, CA, USA). The readings at 540 nm were subtracted from the readings at 450 
nm to correct for optical imperfections in the plate.  
 
3.9 Gene expression analysis 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression of 
genes involved in lipid metabolism, glucose homeostasis, inflammation and oxidative stress in the 
experimental model (Table 3.4). This is one of the most sensitive and specific techniques 
commonly used to study gene expression (Bustin & Mueller, 2005).  
 
3.9.1 RNA extraction 
The 3T3-L1 cells were seeded into 6 well plates and differentiated as described in section 3.3.3. 
Thereafter, media was aspirated, cells were washed with pre-warmed DPBS and 300 µl of QIAzol 
lysis reagent (Qiagen, Hilden, Germany) was added per well and incubated for 5 min at room 
temperature. After incubation, cells were scraped from the plates and triplicate wells were pooled 
into a sterile 2 ml Eppendorf tube and stored at -80°C. For RNA extraction, cells were 
homogenised using stainless steel beads (Qiagen, Hilden, Germany), altering between 2 min at 25 
Hz in the TissueLyser (Qiagen, Hilden, Germany) using pre-cooled adapters and 1 minute on ice. 
Homogenisation was repeated 4 times. Homogenates were centrifuged at 15 000 × g for 10 min at 
4°C (Eppendorf 5415R Centrifuge, Eppendorf, Hamburg, Germany). The supernatant was 




Louis, MO, USA) was added and mixed by shaking the tube for 3 min, followed by centrifugation 
at 15 000 × g for 15 min at 4°C. The upper aqueous phase containing the RNA was transferred to 
a new 1.5 ml Eppendorf tube (this was done carefully without disturbing the white interphase or 
organic phase), 0.5 ml of Isopropanol was added, and the samples were incubated overnight at - 
20°C to precipitate the RNA. The next day, samples were centrifuged at 15 000 × g for 30 min at 
4°C to pellet the RNA. The supernatant was discarded, and the pellet was washed with 70% (v/v) 
ethanol and centrifuged at 15 000 × g for 15 min at 4°C. The wash step was repeated twice. After 
the final wash, the Eppendorf tubes were blotted against paper towel to drain out ethanol and the 
pellet was allowed to air dry. After drying, the RNA pellet was redissolved in 100 μl of RNase-
free water, mixed by pipetting up and down several times, and then incubated at 55°C for 10 min 
to aid resuspension. RNA purification was done using the RNeasy Mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Briefly, 350 μl of RLT lysis buffer was 
added to each RNA sample and mixed by pipetting up and down numerous times, followed by the 
addition of 250 μl of 100% ethanol and mixed as before. The samples were then transferred to 
RNeasy spin columns in 2 ml collection tubes. Spin columns were centrifuged at 13 000 × g for 
15 sec at room temperature to allow RNA to bind, and the flow through was discarded. RPE wash 
buffer (500 μl) was added to the column and centrifuged at 13 000 × g for 15 sec at room 
temperature, and the flow through was discarded. This step was repeated and thereafter, the column 
was transferred to a new 2 ml collection tube and centrifuged at 16 000 × g for 1 min at room 
temperature, to completely dry the column. RNA was eluted by placing the spin column into a 
sterile 1.5 ml collection tube, 50 μl of RNase-free water was added directly to the column 
membrane, and the column was centrifuged for 1 min at 16 000 × g. The elution step was repeated 
as described above in a separate 1.5 ml collection tube to ensure that all the RNA in the membrane 
column was retrieved. The eluted RNA samples were used for RNA quantification and 
subsequently stored at -80°C for future use.  
 
3.9.2 RNA quantification 
RNA concentration and purity were assessed by measuring absorbance at 260 nm (A260) and 280 
nm (A280) using the NanoDrop™ One/OneC microvolume UV-Vis Spectrophotometer (Thermo 




RNA and DNA, while proteins are absorbed at a wavelength of 280 nm. Therefore, the ratio of 
260 nm to 280 nm (A260/280) is used to assess the purity of a sample (Die & Román, 2012). For 
RNA samples, a ratio between 1.8-2.0 is generally accepted as being sufficiently pure. The ratio 
of 260 nm to 230 nm (A260/230) is used as a secondary measure of purity and shows contaminants 
that absorb at or near 230 nm (Die & Román, 2012). For RNA quantification, the pedestal of the 
nanodrop was wiped with a tissue paper and further cleaned with 1 μl of RNase-free water. The 
spectrophotometer was blanked by pipetting 1 μl of RNase-free water onto the pedestal. 
Thereafter, 1 μl of each RNA sample was pipetted onto the pedestal and the absorbance and 
concentration of each sample was read in duplicate and the mean value of the two readings was 
used. 
 
3.9.3 RNA integrity 
High quality RNA is crucial for accurate gene expression results (Imbeaud et al., 2005; Fleige & 
Pfaffl, 2006). The integrity of RNA is assessed by visualisation of the 28S and 18S ribosomal 
RNA bands; a 28S:18S ratio of 2 indicates intact RNA, whereas lower ratios indicate RNA 
degradation. RNA quality and integrity can be assessed using either traditional methods such as 
gel electrophoresis or automated methods such as the Agilent bioanalyser. The Agilent bioanalyser 
is more convenient, sensitive and uses small quantities of RNA samples compared to gel 
electrophoresis (Schroeder et al., 2006). Furthermore, the software calculates the RNA Integrity 
number (RIN) which is based on a numbering system of 1 to 10, with 1 indicating a degraded RNA 
and a RIN number between 7-10 indicating good and intact RNA quality (Schroeder et al., 2006). 
RNA integrity was assessed by the Central Analytical Facilities (CAF), Stellenbosch University, 
Western Cape, SA using the Agilent 2100 bioanalyzer (Agilent Technologies Inc. Waldbronn, 
Germany) and the Agilent RNA 6000 Nano kit. Control RNA (100 ng/μl was included as an 
internal reference), Agilent RNA Nano Ladder and RNA samples were heat denatured for 2 min 
at 70°C, briefly centrifuged and immediately placed on ice. The chip was primed on the priming 
station with Agilent RNA Nano gel-dye mix and 5 μl of Agilent RNA Nano Marker was added to 
all wells including the RNA ladder well. Thereafter, 1 μl of RNA ladder, control or sample was 
added to respective wells. The chip was mixed for 1 minute at 2 400 × g using the IKA vortex 





3.9.4 Reverse transcription 
Total RNA was reverse transcribed into complementary DNA (cDNA) using the High Capacity 
cDNA kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions. Briefly, 1 μg of RNA was added to RNase-free water to a final volume of 10 µl and 
placed on ice. A reverse transcription (RT) reaction mix consisting of nuclease-free water (Ambion 
Inc., Austin, TX, USA), reaction buffer, random primers, dNTPs and reverse transcriptase was 
prepared into separate 2 ml Eppendorf tubes and designated as RT plus. A second reverse 
transcriptase-free reaction mix was made using the same reaction mix with the reverse 
transcription enzyme replaced by water (Table 3.2) and designated as RT minus. RT plus and RT 
minus reaction mixes were mixed by pipetting and the tubes were briefly centrifuged. Thereafter, 
10 μl of RT plus or RT minus reaction mixes were added to 0.2 ml tubes containing 1 µg of each 
of the RNA samples. After brief centrifugation the tubes were placed in a 2720 thermal cycler. 
Reactions were incubated at 25°C for 10 min, 37°C for 3 hrs, and 85°C for 5 sec to inactivate the 
reverse transcriptase enzyme. Samples were stored at -20°C until gene expression analyses by 
qRT-PCR. The amount of genomic DNA contamination was calculated by subtracting RT plus 
from RT minus tube (negative control). 
 
Table 3.2 Reaction components used for reverse transcription  
Component RT plus (μl) RT minus (μl) 
1 μg RNA (in RNase free H2O) 10 10 
10 x RT buffer  2 2 
25 x dNTP mix  0.8 0.8 
10 x random primers  2 2 
Nuclease-free water  3.2 4.2 
Reverse Transcriptase  1 0 





3.9.5 Quantitative real-time PCR 
TaqMan® Gene Expression Assays from Applied Biosystems (Table 3.4) were used to assess the 
expression of genes associated with lipid accumulation, basal lipolysis, inflammation and 
oxidative stress. We used the TaqMan® Gene Expression Assays that span an exon junction to 
avoid the interference of genomic DNA contamination in the PCR (Bustin, 2000; Bustin & Nolan, 
2004), therefore DNase treatment of RNA was not required. TaqMan® Gene Expression assays 
consist of primers and a TaqMan® probe with a FAM™ fluorescent reporter dye on the 5’ end and 
a non-fluorescent quencher dye (NFQ) on the 3’ end of the probe. TaqMan® probes do not 
fluoresce when the reporter and quencher dyes are in close proximity. During a PCR reaction, 
following primer and probe binding, the Taq polymerase cleaves the probe to release the florescent 
reporter from the quencher dye, thereby allowing the detection of the reporter dye fluorescence 
(Arya et al., 2005).  
 
A reaction mixture (final volume of 9 µl) containing 5 µl of TaqMan® universal PCR master mix 
II (Applied Biosystems, Foster City, CA, USA), 0.5 µl of TaqMan® Gene Expression Assay (Table 
3.4) and 3.5 µl of nuclease-free water was prepared (Table 3.3) and scaled up based on the number 
of samples to be analysed. Thereafter, the reaction mix was transferred into the wells of the PCR 
plate, followed by 1 μl of the cDNA samples or the standard curve, which was prepared by making 
a 10-fold dilution series of pooled cDNA (5 µl of each cDNA sample) (Table 3.3).  A no template 
control sample i.e. no cDNA and substituted with 1 µl of nuclease-free water was used as a 
negative control in all PCR reactions. The PCR plates were covered with adhesive film, 
centrifuged briefly at 3 000 × g, mixed by shaking the plate for 5 min on an IKA plate shaker, 
followed by another brief centrifugation at 3 000 × g. Thereafter, the PCR plate was run on an ABI 
7500 sequence detection system instrument (Applied Biosystems, Foster City, CA, USA) using 
the following universal cycling conditions; 50°C for 2 min and 95°C for 10 min, followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 min. Data was analysed using the ABI standard 






Table 3.3 Reaction components for qRT-PCR reactions 
Component  Volume (µl)  
2 × Master mix  5  
TaqMan Gene Expression Assay  0.5  
Water  3.5  
cDNA  1  
Total volume  10  
 
 
Table 3.4 Taqman probes 
Probe Function Assay ID 
Tumour necrosis factor alpha (TNF) Pro-inflammatory Mm00443258_m1  
Adiponectin (ADIPOQ) Anti-inflammatory Mm00456425_m1  
Peroxisome proliferator-activated receptor 
gamma (PPAR) 
Promotes 
adipogenesis Mm00440940_m1  
Acetyl-CoA Carboxylase Alpha (ACACA) Fatty acid synthesis Mm01304257_m1 
Sterol Regulatory Element Binding 
Transcription Factor 1 (SREBF1) 
Promotes 
adipogenesis Mm00550338_m1  
GATA Binding Protein 2 (GATA2) Inhibits adipogenesis Mm00492301_m1  
Hormone sensitive lipase (HSL) Lipolysis Mm00495359_m1  
Nuclear respiratory factor 1 (NRF1) Anti-oxidant   Mm01135606-m1 
NADPH oxidase 4 (NOX4) Pro-oxidant  Mm00479246-m1 
Beta-2-Microglobulin (B2M) Housekeeping genes Mm00437762_m1  







3.10 Data and statistical analysis 
Data was analysed in Microsoft Excel® (Microsoft Office, version 2016, Microsoft Corporation, 
Washington, DC, USA) and GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA). 
Tissue culture data was expressed as the average of three independent experiments, assayed in 
triplicate or more, and represented as the mean ± standard deviation (SD) or as a percentage 
relative to 5.5 mM glucose on day 7 or day 14, which was set as 100%. For treatment, the mean 
values were normalised to the DMSO vehicle control set as 100%. Statistical differences between 
groups were determined one-way analysis of variance (ANOVA) and the Kruskal-Wallis test as 
appropriate with the Tukey or Dunn’s posthoc tests, respectively. A p value of < 0.05 was 

















4.1 Development of the in vitro model 
4.1.1 Lipid accumulation 
To investigate the effect of different glucose concentrations and differentiation times on 
intracellular lipid accumulation, 3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or    
33 mM glucose, and lipid content quantified at day 0 (pre-adipocytes) and after 7 and 14 days 
using ORO staining. Lipid accumulation increased with time in pre-adipocytes cultured with or 
without ADM. Lipid content was significantly higher in adipocytes exposed to 25 mM glucose for 
7 days (1.17 ± 0.30 vs. 0.27 ± 0.07 OD490/CV, p < 0.001) and 33 mM glucose for 14 days (1.07 ± 
0.38 vs. 0.27 ± 0.07 OD490/CV, p = 0.012) compared to pre-adipocytes (Figure 4.1A). At day 7, 
lipid accumulation appeared to be higher with increasing glucose concentrations (Figure 4.1B), 
although differences were not statistically significant. Glucose concentrations did not exhibit any 
significant difference on lipid accumulation at day 14 (Figure 4.1C). The results further show that, 
the long-term exposure of the cells to high glucose (25 mM) in the induced adipogenesis in the 
absence of differentiation cocktail, suggesting that high glucose and incubation time have a 
positive effect on adipogenesis. 
 
4.1.2 Basal lipolysis 
The effect of different glucose concentrations on basal lipolysis was investigated by differentiation 
of 3T3-L1 pre-adipocytes in 5.5 mM, 25 mM or 33 mM glucose and quantification of glycerol 
release, a marker of lipolysis after 0, 7 and 14 days. As expected, glycerol secretion in pre-
adipocytes was lower than in differentiated adipocytes, with statistical significance reached for 25 
mM (6.00 ± 0.37 vs.19.50 ± 7.90 ng/µl, p < 0.001) and 33 mM (6.00 ± 0.37 vs. 21.88 ± 3.83 ng/µl, 
p < 0.001) glucose at 14 days (Figure 4.2A). After 14 days of culture, adipocytes exposed to 5.5 
mM (13.78 ± 3.76 vs. 9.84 ± 1.81 ng/µl, p = 0.022), 25 mM (19.50 ± 7.94 vs. 11.75 ± 2.99 ng/µl, 
p = 0.015) and 33 mM (21.88 ± 3.83 vs. 10.24 ± 2.80 ng/µl, p < 0.001) glucose exhibited higher 
glycerol secretion than adipocytes exposed to those concentrations for 7 days. Comparison of 
adipocytes at 14 days, showed that culture in ADM and 33 mM glucose significantly increased 




glycerol release increased with higher glucose concentrations, the results were not statistically 
significant (Figure 4.2B, C).  
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Figure 4.1 Effect of glucose and differentiation times on lipid accumulation  
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after lipid accumulation was quantified using Oil Red O staining. Lipid accumulation 
was normalised to crystal violet and expressed as absorbance values (A) or relative to 5.5 mM 
glucose, which was set at 100% (B, C). Results are expressed as the mean ± SD of three 
independent experiments, each with n > 3. Significance is depicted as *p < 0.05, ***p < 0.001. 
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Figure 4.2 Effect of glucose and differentiation times on basal lipolysis 
 3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after glycerol release, a marker of lipolysis was quantified using the Glycerol Assay 
Kit. Glycerol concentration is represented in A, while B and C represents the percentage secretion 
at day 7 (A) and day 14 (B) relative to 5.5 mM glucose, which was set at 100%. Results are 
expressed as the mean ± SD of three independent experiments, each with n > 3. Significance is 
depicted as *p < 0.05, ***p < 0.001. 
 
  












































































4.1.3 Oxidative stress 
To assess the effect of different glucose concentrations and differentiation times on oxidative 
status, intracellular ROS production was quantified using DCF fluorescence. DCF fluorescence 
was higher in differentiated compared to undifferentiated adipocytes (Figure 4.3A) and at day 14 
compared to day 7. Adipocytes differentiated in 5.5 mM glucose for 14 days had higher levels of 
ROS compared to adipocytes differentiated for 7 days (22.44 ± 6.06 vs. 16.29 ± 9.46 DCF units, 
p = 0.032). ROS production increased with increasing glucose concentrations (100.00 ± 6.7 vs. 
114.4 ± 12.5 vs. 125.20 ± 17.1 % for 5.5 mM, 25 mM and 33 mM respectively; p < 0.01) at day 7 
(Figure 4.3B) and at day 14 DCF fluorescence was higher at 33 mM compared to 5.5 mM (108.50 
± 17.00 vs. 100.0 ± 17.4 %, p = 0.015) and 25 mM (108.50 ± 17.00 vs. 89.50 ± 21.7 %, p < 0.001) 




To assess the effect of different glucose concentrations and differentiation times on inflammation, 
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose and MCP1, IL6 
and TNFα secretion quantified after 7 and 14 days. MCP1 secretion was significantly higher in 
adipocytes cultured in 33 mM glucose compared to pre-adipocytes (2219.00 ± 178.10 vs. 1800.00 
± 205.20 pg/ml, p=0.005) (Figure 4.4A). Differentiation with varying glucose concentrations for 
7 days did not affect MCP1 secretion (Figure 4.4B). However, after 14 days, differentiation in 33 
mM compared to 5.5 mM (120.20 ± 9.60 vs. 100.00 ± 7.60 %, p=0.007) and 25 mM (120.20 ± 
9.60 vs. 105.20 ± 7.30%, p=0.034) glucose increased MCP1 secretion (Figure 4.4C). TNFα and 
IL6 expression could not be detected.  The kit used to detect TNFα and IL6 was not sensitive 
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Figure 4.3 Effect of glucose and differentiation times on oxidative stress 
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after oxidative stress was measured by quantification of DCF fluorescence. A 
represents fluorescence values, while the percentage fluorescence at day 7 (B) and day 14 (C) are 
expressed relative to 5.5 mM glucose, which was set at 100%. Results are expressed as the mean 
± SD of three independent experiments, each with n > 3. Significance is depicted as *p < 0.05, **p 
< 0.01, ***p < 0.001. 
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Figure 4.4 Effect of glucose and differentiation times on MCP1 secretion 
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after MCP1 secretion, a marker of inflammation was quantified using an enzyme-
linked immunosorbent assay. MCP1 concentration is represented in A, while B and C represents 
the percentage secretion relative to 5.5 mM glucose, which was set at 100%. Results are expressed 
as the mean ± SD of three independent experiments, each with n > 3. Significance is depicted as 
*p < 0.05, **p < 0.01.  
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4.1.5 Mitochondrial activity 
The effect of glucose concentration and differentiation times on mitochondrial activity was 
quantified with the MTT assay. Adipocytes cultured with or without ADM and glucose has 
significantly higher mitochondrial activity compared to pre-adipocytes (all p<0.001) (Figure 
4.5A). Adipocytes differentiated in 33 mM glucose for 14 days had lower MTT activity than those 
cultured for 7 days (2.00 ± 0.15 vs. 2.57 ± 0.16 A570, p<0.001). Increased glucose concentration 
increased MTT activity (p<0.001) after 7 (Figure 4.5B) and 14 (Figure 4.5C) days.  
 
4.1.6 Gene expression 
The quality and purity (Table 4.1) and integrity (Table 4.2) of RNA were within the acceptable 
range. To assess whether genomic DNA was present and could interfere with qRT-PCR results, 
reverse transcription reactions with (plus RT) or without (minus RT) the reverse transcription 
enzyme was subjected to qRT-PCR using primers spanning a single exon. Taq polymerase only 
amplifies double stranded DNA, therefore RNA must be reverse transcribed before it is used as a 
template in PCR. Amplification in the minus RT reactions represent genomic DNA contamination. 
As shown in Table 4.3, a Ct difference of more than 8 was observed between the plus and minus 
RT reactions indicating negligible genomic DNA contamination. The quality of most RNA 
samples was at acceptable range as shown in Table 4.1. Thus, RNA was acceptable to use for qRT-
PCR without DNAse treatment. The slope and R2 (correlation co-efficient) values obtained for the 
Taqman® Gene Expression Assays used in this study were calculated using the standard curve 
(Table 4.4). All slopes (between -3.1 and -3.6) and R2 were within the acceptable range.  
 
Neither differentiation in different glucose concentrations nor time affected the expression of 
genes involved in adipogenesis, basal lipolysis nor lipid metabolism (Figure 4.6). Adiponectin 
expression appeared to be lower with increasing glucose concentrations and after longer culture, 
but differences were not statistically significant (Figure 4.6). The expression of NOX, a marker of 
oxidative stress, was higher in adipocytes cultured for 14 compared to 7 days, with differences at 
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Figure 4.5 Effect of glucose and differentiation times on mitochondrial activity 
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after mitochondrial dehydrogenase activity was measured using the MTT assay. A 
represents absorbance values. All concentrations and differentiation time were significantly 
different to pre-adipocytes. B and C represent the percentage MTT activity expressed relative to 
5.5 mM glucose, which was set at 100%. Results are expressed as the mean ± SD of three 
independent experiments, each with n > 3. Significance is depicted as ***p < 0.001. 
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Table 4.1 RNA concentrations, total yield and purity  
 
Sample ng/l# Total yield (g)† A260/A280 A260/A230 
Day 7 
Undifferentiated 
  Experiment 1 
  Experiment 2 

















5.5 mM Glucose 
  Experiment 1 
  Experiment 2 

















25 mM Glucose 
  Experiment 1 
  Experiment 2 

















33 mM Glucose 
  Experiment 1 
  Experiment 2 

















Day 14  
Undifferentiated 
  Experiment 1 
  Experiment 2 
















5.5 mM Glucose 
  Experiment 1 
  Experiment 2 













25 mM Glucose 
  Experiment 1 
  Experiment 2 













33 mM Glucose 
  Experiment 1 
  Experiment 2 














  #ng/l was calculated using the average of two independent Nanodrop measurements  






Table 4.2 RNA integrity  
Sample 
RIN number 
Experiment 1 Experiment 2 Experiment 3 
Day 7 
  Undifferentiated 
  5.5 mM Glucose 
  25 mM Glucose 

















  Undifferentiated 
  5.5 mM Glucose 
  25 mM Glucose 





































Table 4.3 Assessment of genomic DNA contamination 
Sample Ct (minus RT) Ct (plus RT) Ct difference 
Day 0  








  Undifferentiated 
  5.5 mM Glucose 
  25 mM Glucose 

















  Undifferentiated 
  5.5 mM Glucose 
  25 mM Glucose 
















No template  > 40 
Ct: Threshold cycle for qRT-PCR 
> 40 represents samples where amplification was undetected after 40 cycles of PCR  
 
Table 4.4 Amplification efficiency  
Gene Slope R2 
PPAR -3.53 0.99 
GATA2 -3.723 1.00 
SREBF1 -3.58 1.00 
HSL -3.30 1.00 
ACACA -3.26 1.00 
ADIPOQ -3.51 1.00 
NRF1 -3.41 0.98 
NOX4 -3.43 1.00 
Abbreviations: ACACA, Acetyl-CoA Carboxylase Alpha; ADIPOQ, Adiponectin; GATA2, GATA 
Binding Protein 2; HSL, Hormone sensitive lipase; NOX4, NADPH oxidase 4; NRF1, Nuclear 
respiratory factor 1; PPAR, Peroxisome proliferator-activated receptor gamma; SREBF1, Sterol 
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Figure 4.6 Effect of glucose and differentiation times on adipogenesis, lipid metabolism and 
adipokine genes 
3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after gene expression was quantified using quantitative real time PCR. Expression 
was normalised to the average of B2M and RPL13 and data expressed as arbitrary units. Results 
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Figure 4.7 Effect of glucose and differentiation times on gene expression of oxidative stress 
markers 
 3T3-L1 pre-adipocytes were differentiated in 5.5 mM, 25 mM or 33 mM glucose for 7 and 14 
days, where after gene expression was quantified using quantitative real time PCR. Expression 
was normalised to the average of B2M and RPL13 and data expressed as arbitrary units. Results 
are expressed as the average of three independent experiments, each with n = 3. Significance is 

























































4.2 Treatment with GRT, CPEF, Aspalathin and Mangiferin 
3T3-L1 adipocytes differentiated in 33 mM glucose for 14 days were either treated with GRT, 
CPEF, Aspalathin or Mangiferin acutely for 24 hrs to investigate whether treatment could 
ameliorate or reverse lipid accumulation and basal lipolysis, or chronically in the last 7 days of 
differentiation to investigate the preventative effects of these compounds.   
 
4.2.1 Acute treatment 
To investigate the ameliorative properties of GRT, CPEF, Aspalathin and Mangiferin, 3T3-L1 pre-
adipocytes were differentiated in 33 mM glucose for 14 days (selected from 4.1), where after they 
were treated for 24 hrs. None of the treatments decreased lipid content (Figure 4.8). As expected, 
Isoproterenol, the positive control increased glycerol release. All treatments decreased glycerol 
release, varying between 82-92% (Figure 4.9) and increased mitochondrial activity (Figure 4.10).  
 
4.2.2 Chronic treatment 
To investigate the preventative properties of GRT, CPEF, Aspalathin and Mangiferin, 3T3-L1 pre-
adipocytes were differentiated in 33 mM glucose for 14 days and treated from day 7 to day 14 (last 
7 days of differentiation). As observed for acute treatment, none of the treatments significantly 
decreased lipid content (Figure 4.11). All treatments decreased glycerol release, although this was 
not statistically significant (Figure 4.12). Similarly, as with acute treatment, all treatments 
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Figure 4.8 Effect of acute treatment on lipid content 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose for 14 days, where after adipocytes 
were treated for 24 hours and lipid content was quantified using Oil Red O staining. Lipid content 
was normalised to crystal violet and expressed relative to the vehicle control (DMSO), which was 
set at 100%. Results are expressed as the average ± SD of three independent experiments, each 
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Figure 4.9 Effect of acute treatment on glycerol release 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose for 14 days, where after glycerol 
release, a marker of lipolysis was quantified. Glycerol release was expressed relative to the vehicle 
control (DMSO), which was set at 100%. Isoproterenol was used a positive control. Results are 
expressed as the mean ± SD of three independent experiments, each with n=3. Significance is 
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Figure 4.10 Effect of acute treatment on mitochondrial activity 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose for 14 days, where after 
mitochondrial activity was assessed using the MTT assay. MTT activity was expressed relative to 
the vehicle control (DMSO), which was set at 100%. Results are expressed as the mean ± SD of 
three independent experiments, each with n = 3. Significance is depicted as *p < 0.05, **p < 0.01, 
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Figure 4.11 Effect of chronic treatment on lipid accumulation 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose in the presence of treatment for 14 
days, where after lipid content was quantified using Oil Red O staining. Lipid content was 
normalised to crystal violet and expressed relative to the vehicle control (DMSO), which was set 
at 100%. Results are expressed as the mean ± SD of three independent experiments, each with n = 
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Figure 4.12 Effect of chronic treatment on glycerol release  
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose in the presence of treatment for 14 
days, where after glycerol release, a marker of lipolysis was quantified. Glycerol release was 
expressed relative to the vehicle control (DMSO), which was set at 100%. Results are expressed 
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Figure 4.13 Effect of chronic treatment on mitochondrial activity 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose in the presence of treatment for 14 
days, where after mitochondrial activity was assessed using the MTT assay. MTT activity was 
expressed relative to the vehicle control (DMSO), which was set at 100%. Results are expressed 
as the mean ± SD of three independent experiments, each with n=3. Significance is depicted as *p 





































































































































































4.3 Summary of results 
A summary of the results is presented in Table 4.5 and Table 4.6.  
 
Table 4.5 Results for model development 
Assay 



















Oil Red O Ref   Ref      
Basal lipolysis Ref   Ref   * * * 
Oxidative stress Ref *** *** Ref  *** *   
Inflammation Ref   Ref  *    
Mitochondrial 





























































































*p < 0.05, **p < 0.01 and ***p < 0.001 compared to 5.5 mM (Day 7 or Day 14) or Day 14 vs. Day 
7. 
 increased;  decreased;  no difference.  
Abbreviations: ACACA, Acetyl-CoA Carboxylase Alpha; ADIPOQ, Adiponectin; GATA2, GATA 
Binding Protein 2; HSL, Hormone sensitive lipase; NOX4, NADPH oxidase 4; NRF1, Nuclear 
respiratory factor 1; PPAR, Peroxisome proliferator-activated receptor gamma; Ref, Reference; 






Table 4.6 Results of treatment 
Treatment  
Lipid accumulation Basal lipolysis 
Mitochondrial 
activity 
Acute Chronic Acute  Chronic Acute Chronic 
GRT 
  0.1 µg/ml 
  1 µg/ml 
  10 µg/ml 
































    0.1 µM 
    1 µM 
    10 µM 
































    0.1 µg/ml 
    1 µg/ml 
    10 µg/ml 
































    0.1 µM 
    1 µM 
    10 µM 
































*p < 0.05, **p < 0.01 and ***p < 0.001 compared to 5.5 mM (Day 7 and Day 14) or Day 14 vs. 
Day 7 
 increased;  decreased;  no difference.  


















Obesity is considered one of the greatest health challenges of the 21st century, despite the 
availability of several anti-obesity strategies. In recent years, plant polyphenols have attracted 
increasing interest as more effective and potentially safer anti-obesity therapeutics. However, the 
first-line screening of these compounds is hampered by the shortage of in vitro experimental 
models that mimic the complex pathophysiology of obesity in vivo. This study, firstly, examined 
the effects of glucose concentration and differentiation times on lipid accumulation, basal lipolysis, 
oxidative stress and inflammation, and secondly, investigated the ameliorative effects of 
Aspalathus linearis, Cyclopia intermedia and their major polyphenols, Aspalathin and Mangiferin, 
against these conditions.  
 
5.1 Model development 
5.1.1 Lipid accumulation 
Exposure to high glucose concentrations increased lipid accumulation after 7 days, however, this 
effect was not observed after long-term culturing (14 days). The role of glucose in accelerating 
adipocyte differentiation and promoting the formation of lipid droplets is widely reported. Aguiari 
et al. reported that culturing adipocyte derived stem cells (ADSCs) in 25 mM glucose is sufficient 
to induce adipogenesis and adipocyte maturation (Aguiari et al., 2008). Adipogenesis is a multi-
step process, encompassing a cascade of cell-cycle proteins and nuclear transcription factors such 
as PPAR that regulate gene expression, leading to morphological changes, cell arrest, mitosis, 
lipid accumulation and metabolic function (Gustafson et al., 2009). The effect of varying glucose 
concentrations in combination with the standard adipogenesis inducing cocktail, as used in this 
study, has been reported previously. Differentiation of 3T3-L1 adipocytes (Lin et al., 2005; Han 
et al., 2007) and MSCs (Chuang et al., 2007) in 25 mM compared to either 4, 5 or 5.5 mM glucose 
increased lipid accumulation and adipocyte hypertrophy. Palacios-Ortega et al. reported that lipid 
accumulation increased in 3T3-L1 pre-adipocytes differentiated in 25 mM compared to 5 mM 
glucose (Palacios-Ortega et al., 2016). Shilpa and co-authors reported that exposure to 25, 45, 65, 
85, and 105 mM increased lipid accumulation by approximately 45.7%, 170.4%, 237.8%, 139.8% 




similarly showed increased lipid accumulation compared to pre-adipocytes and modest effects 
were observed with increasing glucose concentrations, acknowledging that our concentrations 
were much lower than that used by Shilpa et al. (Shilpa, Dinesh & Lakshmi, 2013). Consistent 
with our findings, the high glucose-induced lipid accumulation reported by (Palacios-Ortega et al., 
2016) was evident at 7 days, but not after long-term culturing (21 days), suggesting that adipocytes 
have probably saturated their lipid storage capacity after 7 days. Alternatively, continuous 
exposure to high glucose until day 14, possibly induced glucotoxicity stress, thus inhibiting the 
differentiation of 3T3-L1 pre-adipocytes into functional adipocytes with lipid storage capacity 
(Rharass & Lucas, 2019). No changes in adipogenic and lipogenic gene expression (PPARγ, 
SREBF1, ACACA and GATA2) was observed. PPARγ is essential during the early stages of 
adipocyte differentiation, however, is not required or has lesser importance for the maintenance of 
differentiated adipocytes, which could explain the lack of significant differences between days 7 
and 14 (Liao et al., 2007; Kolodziej et al., 2019). In concurrence to our findings, Kolodziej et al., 
reported that a prolong incubation of fat with high glucose concentration intensifies the degree of 
differentiation in mature adipocytes, however, have no effect on PPAR-γ expression (Kolodziej et 
al., 2019). Functional studies by Liao and colleagues provided the evidence that a PPAR-γ 
knockdown inhibited adipocyte differentiation however, PPAR-γ was not required for 
maintenance of the adipocyte differentiation state post adipogenesis in 3T3-L1 (Liao et al., 2007).  
 
5.1.2 Basal lipolysis 
Exposure to different glucose concentrations had a modest effect on basal lipolysis, which 
appeared to be induced by extended differentiation times at all glucose concentrations tested. 
Increased basal lipolysis at day 14 compared to 7 was statistically significant when adipocytes 
were differentiated in 33 mM glucose, and accompanied by a small, although not statistically 
significant increase in HSL gene expression. Lipolysis is a normal physiological function of 
adipocytes in response to energy demands, such as fasting or physical exercise, allowing 
adipocytes to mobilise their fat stores for use by other organs (Morigny et al., 2016). During 
lipolysis, triacylglycerols are hydrolysed into FAs and glycerol through a sequential process 
catalysed by three major lipases, of which HSL is key. During obesity however, lipolysis is 




insulin resistance have been proposed. First, increased FA secretion from adipocytes may lead to 
lipid accumulation in insulin-sensitive tissues such as the liver and muscle, thus impairing insulin 
sensitivity (Samuel & Shulman, 2016). Second, increased lipolysis may dysregulate adipokine 
secretion and affect insulin sensitivity (Ertunc et al., 2015). Third, higher levels of circulatory FAs 
may lead to inflammation through their pro-inflammatory stimulating effects on macrophages 
(Suganami, Nishida & Ogawa, 2005). Green et al. reported that high glucose concentrations 
markedly increased the lipolytic action of TNF (Green et al., 2004). Furthermore, these authors 
report that glucose alone did not cause a substantial increase in lipolysis, however, the addition of 
TNF to the culture medium enhanced the lipolytic effect of glucose. These findings suggest that 
future experiments should investigate whether the addition of TNF will further induce lipolysis 
in our model. The activity of HSL is regulated by protein phosphorylation (Krintel et al., 2009; 
McDonough et al., 2011), thus future studies should quantify protein levels.  
 
White adipocytes are capable of producing large amounts of lactate and glycerol from glucose 
(Rotondo et al., 2017). Thus, the increased glycerol concentration observed on day 14 compared 
to day 7 could be due to prolonged exposure to excess glucose concentrations, which result in the 
synthesis and secretion of glycerol via glycerogenesis (Del Mar Romero et al., 2015; Rotondo et 
al., 2017). Other markers of lipolysis such as FA secretion need to be quantified to ascertain 
whether the increase in glycerol levels are due to triacylglycerol breakdown to FA and glycerol 
via lipolysis.   
 
5.1.3 Oxidative stress 
Differentiation in higher glucose concentrations increased oxidative stress at day 7, with modest 
effects and increased NOX4 expression observed at day 14. Obesity is associated with increased 
ROS production and oxidative stress in adipose tissue (Dludla et al., 2019). Oxidative stress 
induces cellular damage by oxidising cellular constituents such as proteins, lipids and DNA. NOX 
is the main source of ROS production in adipocytes (Bedard & Krause, 2007), catalysing the 
transfer of electrons from NADPH to  oxygen, thus generating superoxide anion (O2-), which is 




reported that high glucose concentrations increase ROS production in adipocytes, which could be 
due to the excess glucose influx to the glycolytic pathway resulting in NADH production, an 
electron carrier of the mitochondrial electron transport chain (Yan, 2014). Lin et al. showed 
increased ROS production in 3T3-L1 adipocytes differentiated in 25 mM compared to 4 mM 
glucose, and in adipocytes isolated from hyperglycaemic mice compared to controls (Lin et al., 
2005). Aguiari et al. reported that ADSCs differentiate into adipocytes when cultured in 25 mM 
glucose, with a concomitant increase in ROS production compared to ADSCs cultured in 5 mM 
glucose (Aguiari et al., 2008). Furukawa et al. demonstrated increased ROS production in 
adipocytes from obese mice and in 3T3-L1 adipocytes cultured with FAs (Furukawa et al., 2004). 
In both instances, higher ROS levels was accompanied by increased NOX4 expression, consistent 
with our findings after 14 days of culture. Several studies have reported that intracellular ROS are 




Exposure to different glucose concentrations had a modest effect on MCP1 secretion at day 14, 
but not at day 7. Adipocytes differentiated in 33 mM glucose had the highest levels of MCP1 
secretion.  Obesity is associated with chronic low-grade inflammation, partly attributed to the 
infiltration of pro-inflammatory macrophages into adipose tissue (Boutens & Stienstra, 2016). 
Increased expression of MCP1 has been demonstrated in adipose tissues and plasma of obese 
individuals. Mice knockout studies showed that the secretion of MCP1 from adipocytes directly 
trigger the recruitment of macrophages into adipose tissue, which in turn secrete a variety of 
chemokines and cytokines that further promote a local inflammatory response and systemic insulin 
resistance (Kanda et al., 2006). Consistent with our findings at day 14, Han et al., (2007) reported 
increased expression of MCP1 and serum amyloid A, another protein involved in macrophage 
recruitment, in adipocytes cultured in 25 mM compared to 5 mM glucose. Furthermore, our 
findings are similar to (Han et al., 2007) who reported that exposure of 3T3-L1 adipocytes to high 
glucose concentrations (25 mM) increased MCP1 secretion but had no effect on TNF secretion. 
Similarly, He et al. also did not observe increased TNF secretion in human adipose tissue exposed 




secretion in this study, suggesting that pro-inflammatory cytokine secretion in adipose tissue is 
mainly driven by infiltrated macrophages rather than by adipocytes. Future experiments should 
focus on co-culturing adipocytes and macrophages to explore this hypothesis. It is possible that 
TNFα and IL6 values may have been below the detection range of the kit, or alternatively the assay 
did not work and the inclusion of a positive control (such as lipopolysaccharide) may have shed 
light on the reason for our failure to detect these cytokines. Although the differences were not 
statistically significant, the expression of ADIPOQ was lower with increasing glucose 
concentrations and after day 14. Adiponectin is an adipokine mainly produced and secreted by 
adipose tissue that regulates insulin sensitivity and anti-inflammatory response (Lihn, Pedersen & 
Richelsen, 2005; Ouchi & Walsh, 2007). The expression of adiponectin is reduced during obesity 
and intermittent exposure of 3T3-L1 adipocytes to high glucose (alternating between 5 and 20 
mM) exacerbated the suppression of ADIPOQ expression and secretion compared to culture at 
constant high glucose (20 mM) (Sun et al., 2010). 
 
5.1.5 Mitochondrial activity 
Exposure to higher glucose concentrations increased mitochondrial dehydrogenase activity in 3T3-
L1 adipocytes after 7 and 14 days. Mitochondria play a critical role in metabolic disease 
(Johannsen & Ravussin, 2009), with conflicting reports on whether increased or decreased 
mitochondrial activity is associated with disease. Tanis et al. showed differences in mitochondrial 
bioenergetics (increased respiration) between 3T3-L1 adipocytes cultured in 5 mM and 30 mM 
glucose (Tanis et al., 2015). Palacios-Ortega et al. reported no change in mitochondrial activity 
after long-term glucose exposure, however high glucose concentrations decreased cell viability 
compared to short-term culture (Palacios-Ortega et al., 2016). Low glucose (5.5 mM) had 
decreased MTT activity compared to 25 mM and 33 mM glucose at both day 7 and 14, suggesting 
that deficiency in glucose induces stress or glucose starvation in these cells hence the 






The second aim of the study was to investigate the ameliorative effects of Aspalathus linearis 
(GRT), Cyclopia intermedia (CPEF), Aspalathin and Mangiferin against lipid accumulation and 
basal lipolysis. These effects were assessed using both an acute and chronic treatment protocol. 
Acute treatment assessed whether GRT, CPEF, Aspalathin and Mangiferin treatments exhibit 
therapeutic effects in reversing adipocyte dysfunction induced by high glucose (33 mM) exposure 
for 14 days. Chronic treatment assessed whether GRT, CPEF, Aspalathin and Mangiferin 
treatments have preventative effects on adipocyte dysfunction induced by high glucose (33 mM) 
exposure for 14 days. Acute and chronic treatments showed similar effects on lipid accumulation, 
basal lipolysis and mitochondrial dehydrogenase activity. Both acute and chronic treatments did 
not reduce lipid accumulation and mitochondrial dehydrogenase activity, while they both 
decreased basal lipolysis. This suggests that length of exposure to GRT, CPEF, Aspalathin and 
Mangiferin treatment was not a contributing factor to the lack of bioactivity observed in response 
to treatment with GRT, CPEF, Aspalathin and Mangiferin.  
 
5.2.1 Lipid accumulation 
Neither acute nor chronic treatment with GRT, CPEF, Aspalathin or Mangiferin affected lipid 
accumulation, in contrast to previous studies that reported their ability to decrease lipid content 
through inhibition of adipocyte differentiation and expression of adipogenic genes such as PPAR 
and SREBF1 (Dudhia et al., 2013; Pheiffer et al., 2013; Zhang et al., 2013; Sanderson et al., 2014; 
Mazibuko et al., 2015; Jack et al., 2017). Dudhia et al. assessed the effect of an aqueous extract of 
“fermented” C. maculata and aqueous extracts of “unfermented” C. maculata and C. subternata 
on obesity in differentiating 3T3-L1 pre-adipocytes and demonstrated that these extracts dose-
dependently inhibited adipogenesis, lipid accumulation, triglyceride content and peroxisome 
proliferator-activated receptor gamma (PPARγ) expression (Dudhia et al., 2013). The aqueous 
extract of “fermented” C. maculata also stimulated lipolysis and increased hormone sensitive 
lipase (HSL) and perilipin expression in mature 3T3-L1 adipocytes (Pheiffer et al.,2013). More 
recently, Jack et al. reported that a crude polyphenol-enriched fraction of Cyclopia intermedia 
(CPEF) decreased lipid content, and increased Hsl and uncoupling protein 3 (Ucp3) gene 




deficient (Leprdb/db) mice (Jack et al., 2017). Sanderson et al. showed that rooibos inhibits 
adipogenesis and intracellular lipid accumulation in 3T3-L1 adipocytes, accompanied by 
decreased expression of adipogenesis and lipid accumulation genes and proteins (Sanderson et al., 
2014). Similarly, Mangiferin decreases triglycerides and FAs in 3T3-L1 adipocytes through the 
decreased expression of SREBP and HSL (Zhang et al., 2013). The disparities could be due to the 
differences in culture conditions. For example, Jack et al. differentiated 3T3-L1s in 25 mM glucose 
for 7 days, whereas we exposed cells to 33 mM for 7 day or 14 days (Jack et al., 2017). We 
recommend that treatment conditions be standardised across studies to prevent the conflicting 
results that are widely reported. Interestingly, studies conducted in Vervet monkeys, similarly 
reported that treatment with GRT did not decrease triglyceride content in diabetic and non-diabetic 
monkeys (Orlando et al., 2019). Thus, our findings suggest that these compounds may not decrease 
lipid content, but rather may have ameliorative properties against oxidative stress, as reported by 
(Orlando et al., 2019). 
 
5.2.2 Basal lipolysis 
Treatment with GRT, CPEF, Aspalathin and Mangiferin (both acute and chronic) reversed the 
basal lipolysis induced by differentiating 3T3-L1 adipocytes in 33 mM glucose for 14 days. Studies 
on polyphenols and lipolysis have reported conflicting results. Jack et al. reported that CPEF 
increases lipolysis in 3T3-L1 adipocytes (Jack et al., 2017), while Pheiffer et al. reported that 
Cyclopia maculata increases lipolysis, which is accompanied by an increase in the expression of 
HSL (Pheiffer et al., 2013). Similar results were reported for Mangiferin in obese rats (Yoshikawa 
et al., 2002). However, antilipolytic effects have also been reported. Zhang et al. reported that 
Mangiferin exerts its anti-obesity effects by decreasing both lipid content and lipolysis (Zhang et 
al., 2013). While Sanderson et al. demonstrated that a fermented rooibos extract inhibits 
adipogenesis, lipolysis and improves glucose uptake (Sanderson et al., 2014). Once again, the 
discrepant results between studies could be due to different culture conditions and varying 
polyphenol content of plant extracts. Furthermore, results are affected by several factors including 
treatment time and dose, extraction procedure and the stressors used to induce the experimental 
model (Beltrán-Debón et al., 2011).  Surprisingly, we did not observe a decrease in lipid content, 




in lipid content, thus future work should measure intracellular triglyceride levels. Decreased 
lipolysis and FAs in the circulation improves insulin sensitivity in peripheral organs such as the 
liver and muscle (Girousse et al., 2013). Our results suggest that the antilipolytic activity of these 
treatments may be a promising therapeutic agent for treating insulin resistance and metabolic 
disease.  
 
5.2.3 Mitochondrial activity 
Acute and chronic treatment with GRT, CPEF, Aspalathin and Mangiferin did not decrease 
mitochondrial dehydrogenase activity, with slight increases observed at specific concentrations. 
The MTT assay is widely used to assess the cytotoxicity of extracts or compounds. None of the 
treatments induced toxic effects, suggesting that the decrease in lipolysis is not due to cell death, 
but rather the effect of the treatment. A study by Mazibuko et al. similarly showed that GRT and 
Aspalathin increases MTT activity and basal intracellular ATP content (Mazibuko et al., 2015). 
 
5.3 Strengths and limitations 
The study is a comprehensive analysis of the effects of varying glucose concentration and 
maturation time on various obesity associated conditions and may lead to the development of a 
more relevant in vitro model. Furthermore, we provide new information about the therapeutic 
potential of GRT, CPEF, Aspalathin and Mangiferin against these conditions. However, the study 
also has several limitations. First, due to technical challenges with our microscope, we were not 
able to capture ORO images, thus could not visualise lipid content and adipocyte hypertrophy. 
Second, we did not correct for osmolarity, which can lead to oxidative stress. High glucose 
concentrations increase osmotic pressure and induces glucotoxicity, thus controlling for 
osmolarity using mannitol is recommended. Glucose concentrations in this study were lower than 
used in other studies and did not induce cytotoxicity, as assessed with the MTT assay. However, 
the effect of osmolarity should be acknowledged and future studies should control for osmotic 
pressure. Third, ROS was assessed using DCF, which is a rapid and cost-effective method of 
quantification.  However, it is not as sensitive as flow cytometry, and presents another weakness 




(ROS) and antioxidants, thus assays measuring the total redox (both ROS and total anti-oxidant 
capacity) may be better indicators of oxidative stress that should be considered for future. NOX4 
gene expression, however, supported the increased oxidative stress observed with DCF. Fourth, 
protein expression was not assessed. Gene expression does not necessarily correlate with protein 
levels due to post-translational and translational modifications such as phosphorylation 
(Tokmakov et al., 2012). Fifth, due to time and resource constraints, we did not investigate the 
effect of treatments against oxidative stress and inflammation. The MTT assay offers challenges 
when using polyphenols. The colour emitted by polyphenols may interfere with the assay and 
underestimate the results obtained, thus the use of controls consisting of polyphenols, without cells 
should be used (Wisman et al., 2008). Treatment with GRT, CPEF, Aspalathin and Mangiferin 
unexpectedly showed similar effects on lipolysis (i.e. all four treatments decreased lipolysis to the 
same levels), which could be due to polyphenols in the samples interfering with the assay by 
inhibiting enzymes in the glycerol assay kit. Future studies using diluted samples are 
recommended to minimize enzyme inhibition. Lipolysis, oxidative stress and inflammation assays 
were not normalized in this study. Normalization to total protein content or cell viability are 
essential to reduce experimental variability and improve data comparisons and statistical 
significance. Lastly, it is important to include positive controls such as rosiglitazone and hydrogen 




Both glucose concentration and differentiation times affect lipid accumulation, basal lipolysis, 
oxidative stress and inflammation, although these vary according to the parameter measured. 
Differentiation of adipocytes in 33 mM glucose for 14 days represents an in vitro model that may 
more closely mimic the in vivo situation. GRT, CPEF, Mangiferin and Aspalathin decreased basal 
lipolysis, supporting the therapeutic potential of Aspalathus linearis and Cyclopia intermedia 
against metabolic disturbances induced by obesity. Obesity is associated with an increase in basal 
lipolysis and FAs, which leads to insulin resistance in peripheral tissues such as the skeletal muscle 




from other tissues are required to gain insight into the mechanisms and relationship between 
lipolysis and insulin sensitivity.  
 
5.5 Future work   
The limitations of the study should be addressed in future work: 
• Microscopy to measure adipocyte hypertrophy;  
• Measure intracellular triglycerides;  
• Use mannitol to correct for osmotic pressure;  
• Quantify oxidative stress in our model using a more sensitive approach such as flow 
cytometry;  
• Measure the effects of GRT, CPEF, Aspalathin and Mangiferin against oxidative stress and 
inflammation; and 
• Assess protein expression.   
In addition, future work should consider including TNF as an inducer to exacerbate the effect of 
glucose concentration in our model. Furthermore, it is important to examine the relationship 
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7.1 Aseptic technique 
During cell culture, aseptic technique is important to prevent contamination of cells from foreign 
microorganisms (viruses, bacteria and fungi). Personal protective equipment, which included a 
clean laboratory coat, gloves, shoe covers, a face mask and arm sleeve covers were worn to reduce 
the risk of contamination. Cell culture procedures were carried out in a biosafety level 2 cabinet, 
which was cleaned with 70% ethanol prior to use. The work area was kept tidy and contained only 
the necessary reagents and consumables for the specific procedure to be conducted. All reagents 
and consumables such as flasks, pipettes and plates were wiped down with 70% ethanol. 
Consumables that were not properly sealed were considered non-sterile and therefore they were 
not used. Glass pipettes were sterilised with a Bunsen burner. To ensure a clean environment in 
and outside of the hood, incubators, the floor, work surfaces and equipment were cleaned twice a 





7.2 Reagents and kits  





diphenyltetrazolium bromide (MTT) M2003 Sigma-Aldrich, St Louis, MO, USA 
3-isobutyl -1-methyl-xanthine (IBMX) I5879 Sigma-Aldrich, St Louis, MO, USA 
3T3-L1 pre-adipocytes  CL-173 
American Type Culture Collection 
(ATCC), Manassas, VA, USA 
Chloroform 136112-00-0 Sigma-Aldrich, St Louis, MO, USA 
Dexamethasone D4902 Sigma-Aldrich, St Louis, MO, USA 
Dimethyl sulfoxide (DMSO) 276855 Sigma-Aldrich, St Louis, MO, USA 
Dulbecco`s modified Eagle`s medium (5.5 
mM glucose) (DMEM) 22320030 
Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Dulbecco`s modified Eagle`s medium (25 
mM glucose) (DMEM) 11995073 
Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Dulbecco`s phosphate buffered saline 
(DPBS) 17-513F Lonza, Walkersville, MD, USA 
Ethanol (for cleaning) 2875 Sigma-Aldrich, St Louis, MO, USA 
Ethanol absolute, 200 molecular grade E7023-500 Sigma-Aldrich, St Louis, MO, USA 
Foetal bovine serum 16140071 
Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Hanks buffered saline solution (HBSS) 08-003A Lonza, Walkersville, MD, USA 
Glucose powder D5030 Sigma-Aldrich, St Louis, MO, USA 
Insulin I92785 Sigma-Aldrich, St Louis, MO, USA 
Isopropanol I9516 Sigma-Aldrich, St Louis, MO, USA 
Oil Red O (ORO) 1320-06-5   Sigma-Aldrich, St Louis, MO, USA 




Sodium bicarbonate (NaHCO3)   M2645 Sigma-Aldrich, St Louis, MO, USA 
Sterile TC water 59900C Lonza, Walkersville, MD, USA 
Qiazol reagent 79306 Qiagen, Hilden, Germany 
Trypan blue 15050-065 Invitrogen, Carlsbad, CA, USA 
Trypsin 17-161F Lonza, Walkersville, MD, USA 
TaqMan® universal PCR master mix II 4364338 




Table 7.2 List of kits 
Kits Catalogue number Supplier 
DuoSet ELISA Ancillary 
Reagent Kit 2 DY008 
R&D Systems, Minneapolis, MN, 
USA 
Glycerol assay kit   MAK211 Sigma-Aldrich, St Louis, MO, USA 
Mouse IL6 DuoSet ELISA DY406 
R&D Systems, Minneapolis, MN, 
USA 
Mouse MCP1 DuoSet ELISA DY479-05 
R&D Systems, Minneapolis, MN, 
USA 
Mouse TNF DuoSet ELISA DY410 
R&D Systems, Minneapolis, MN, 
USA 
RNeasy mini kit 74106 Qiagen, Hilden, Germany 
Turbo DNase kit  AM1907 Ambion Inc, Austin, TX, USA 
High Capacity cDNA kit  4368814 







7.3 List of equipment and software 
Table 7.3 List of equipment and consumables 
Equipment  Catalogue number Supplier 
Agilent 2100 Bioanalyzer  76337 
Agilent Technologies, Waldbronn, 
Germany 
Biohazard safety cabinet, class II EN 12469 Airvolution lab, Johannesburg, SA 
BioTek® ELX 800 plate reader 7341000 
BioTek Instruments Inc., Winooski, 
VA, USA  
Carbon dioxide (CO2) K239C Air Products, Centurion, Gauteng, SA 
CELLBIND 6-well plates 3335 Corning, Tewksbury, MA, USA 
CELLBIND 24-well plates 3337 Corning, Tewksbury, MA, USA 
CELLBIND 96-well plates 3300 Corning, Tewksbury, MA, USA 
Eppendorf centrifuge 5810 R 5810000420 Sigma-Aldrich, St Louis, MO, USA 
Cryotubes 430659 Corning, Tewksbury, MA, USA 
Eppendorf tubes 30123301 Sigma-Aldrich, St Louis, MO, USA 
Filter Pads 23385 Sigma-Aldrich, St Louis, MO, USA 
Galaxy R CO2 incubator,  CO170R-120-0000 RS Biotech, West Lothian, UK 
IKA vortex mixer  0030000753 IKA, Staufen, Germany 
NanoDrop OneC Microvolume 
UV-Vis spectrometer  ND-ONE 
Thermo Fisher Scientific, Waltham, 
MA, USA 
Olympus inverted light 
microscope CKX 41 Melville, NY, USA 
PCR plates N8010560 
Applied Biosystems, Foster City, CA, 
USA 
Stainless steel beads (5mm) 69989 Qiagen, Hilden, Germany 





Table 7.4 List of software 
Software Description Manufacturer 
GraphPad Prism 7 GraphPad Software La Jolla, CA, USA 
BioTek plate reader  Gen5 software (version 1.05) 
BioTek Instruments Inc., 
Winooski, USA 
Microsoft office Excel / Word / PowerPoint 
Microsoft Corporation, WA, 
USA 
SpectraMax® i3x Multi-Mode 
Microplate reader SoftMax Pro 7 Software 
Molecular Devices, 
Sunnyvale, CA, USA 
ABI Thermal cycler Software (SDS V1.4) 
Applied Biosystems, Foster 







7.4 Preparation of medium and buffers  
Table 7.5 Preparation of medium  
Medium Reagents  Concentration Volume (50 ml) 
Growth medium 
FBS 10% 5 ml 
DMEM 5.5, 25 or 33 mM 45 ml 
Freezing medium 
FBS 10% 5 ml 
DMEM 25 mM 41.5 ml 
DMSO 7% 3.5 ml 
Differentiation 
media 
DMEM 5.5, 25 or 33 mM 49.49 ml 
IBMX 0.5 mM 0.5 ml 
Insulin 1 µg/ml 0.005 ml 
Dexamethasone 1 µM 0.005 ml 
Insulin Medium 
Insulin 1 µg/ml 0.005 ml 
DMEM 5.5, 25 or 33 mM 49.995 ml 
Media were freshly prepared on each day of differentiation and freezing 
 
 
Table 7.6 Preparation of DMEM without phenol red 
Medium MW (g/mol) Concentration Amount/1L 
DMEM powder - 8.3 g/L 8.3 g 
BSA (no fatty acids) - 0.1% 1 g 
NaHCO3  84.01 3.7 g/L 3.7 g 







Table 7.7 Sorenson's buffer 
Reagent Final Concentration  g/100 ml 
Glycine 0.1 M 0.751 g 
NaCl 0.1 M 0.584 g 





7.5 Assays  
7.5.1 Preparation of the ORO and CV stains 
A) ORO: 
A 1% (w/v) ORO stock solution was prepared by dissolving 1 g of the ORO powder in 100 ml 
of isopropanol. This solution was placed on a magnetic stirrer overnight to dissolve most of 
the ORO powder. A 70% (v/v) working solution was prepared by adding 30 ml of distilled 
H2O to 70 ml ORO stock solution. The ORO working solution was mixed by inversion and 
then sterile filtered to remove all the precipitates. The ORO working solution was stored at 
room temperature away from direct sunlight. 
B) CV: 
A 2% CV stock solution was prepared by dissolving 2 g CV powder in 100 ml of tissue culture 
grade H2O. The CV stock solution was placed on a magnetic stirrer overnight (~16 hrs). A 
0.5% working solution was prepared by adding 49.75 ml of distilled H2O to 250 µl of the CV 
stock solution and then mixed by inversion. A fresh CV working solution was prepared for 
every experiment on the day of the experiment. 
 
7.5.2 Preparation of the MTT 
• 13 mg of MTT dye was weight and dissolved in 6.5 ml of DPBS to make a 2 mg/ml stock. 






Table 7.8 Treatments 




Afriplex (Pty) Ltd, Paarl, Western 
Cape, SA 
Aspalathin  
Major compound from 
Aspalathus linearis 
High Force Research Ltd., Durham, 
England, UK 
Crude polyphenol enriched 
fraction of Cyclopia intermedia 
Unfermented Cyclopia 
intermedia Babalwa Jack (Jack et al., 2017) 
Mangiferin 
Major compound from 
Cyclopia 
Sigma-Aldrich, St Louis, MO, 
USA 
Isoproterenol  β-Adrenoceptor agonist 






7.7 Supplementary data 
 
 
Figure 7.1 Effect of acute treatment on cell density. 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose in the presence of treatment for 14 
days, where after cell density was assessed using the crystal violet (CV) staining. CV was 
expressed relative to the vehicle control (DMSO), which was set at 100%. Results are expressed 






Figure 7.2 Effect of chronic treatment on cell density. 
3T3-L1 pre-adipocytes were differentiated in 33 mM glucose in the presence of treatment for 14 
days, where after cell density was assessed using the crystal violet (CV) staining. CV was 
expressed relative to the vehicle control (DMSO), which was set at 100%. Results are expressed 
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